

---

## Appendices A–G

Appendix A:	Scope for the development of the clinical guideline .....	3
Appendix B:	Declarations of interests by Guideline Development Group members .....	14
Appendix C:	Special advisors to the Guideline Development Group .....	24
Appendix D:	Stakeholders who submitted comments in response to the consultation draft of the guideline .....	25
Appendix E:	Researchers contacted to request information about unpublished or soon-to-be published studies .....	27
Appendix F:	Analytic framework, review questions and review protocols .....	29
Appendix G:	Research recommendations .....	76

*The following appendices can be found in separate files:*

Appendix H:	Clinical evidence – search strategies
Appendix I:	Health economic evidence – search strategies
Appendix J:	Clinical evidence – completed methodology checklists for assessment studies
Appendix K:	Clinical evidence – examples of study characteristics data extraction and methodology checklists
Appendix L:	Clinical evidence – study characteristics, measure characteristics and excluded evidence for all assessment studies
Appendix M:	Clinical evidence – study characteristics, methodology checklists and outcomes for risk factor review
Appendix N:	Clinical evidence – study characteristics, methodology checklists, outcomes and comparisons for all intervention studies
Appendix O:	Clinical evidence – GRADE evidence profiles for all studies
Appendix P:	Clinical evidence – forest plots for all studies
Appendix Q:	Clinical evidence – excluded studies
Appendix R:	Health economic evidence – completed health economics checklists
Appendix S:	Health economic evidence – evidence tables
Appendix T:	Health economic evidence – economic profiles
Appendix U:	Service user focus-group report
Appendix V:	Carer focus-group report
Appendix W:	Additional health economics results

## Abbreviations

AEI	Australian Education Index
ASSIA	Applied Social Sciences Index and Abstracts
BEI	British Education Index
CB	challenging behaviour
CBLD	challenging behaviour and learning disabilities
CDSR	Cochrane Database of Systematic Reviews
CENTRAL	Cochrane Central Register of Controlled Trials
CI	confidence interval
CINAHL	Cumulative Index to Nursing and Allied Health Literature
DSM(-IV, -V)	Diagnostic and Statistical Manual of Mental Disorders (fourth edition, fifth edition)
Embase	Excerpta Medica Database
ERIC	Education Resources Information Center
GDG	Guideline Development Group
GRADE	Grades of Recommendation Assessment, Development and Evaluation
IBSS	International Bibliography of the Social Sciences
ICD(-10, -11)	International Statistical Classification of Diseases and Related Health Problems (10 <sup>th</sup> revised edition, 11 <sup>th</sup> revised edition)
IQ	intelligence quotient
ITT	intention to treat
k	number of studies
MEDLINE	Medical Literature Analysis and Retrieval System Online
N	total number of participants
NCCMH	National Collaborating Centre for Mental Health
NHS	National Health Service
NICE	National Institute for Health and Care Excellence
OR	odds ratio
PreMEDLINE	in-process and other non-indexed citations from MEDLINE
PROSPERO	prospectively registered systematic reviews in health and social care
PsycINFO	Psychological Information Database
RCT	randomised controlled trial
ROB	risk of bias
RQ	review question
SD	standard deviation
SSCI	Social Sciences Citation Index

# Appendix A: Scope for the development of the clinical guideline

## A.1 Guideline title

Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges

### A.1.1 Short title

Challenging behaviour and learning disabilities

### A.1.2 The remit

The Department of Health has asked NICE to prepare a clinical guideline on 'challenging behaviour in people with learning disability.'

## A.2 Clinical need for the guideline

### A.2.1 Epidemiology

- a) Learning disabilities are heterogeneous conditions, but are defined by 3 core criteria: lower intellectual ability (usually defined as an IQ of less than 70), significant impairment of social or adaptive functioning and onset in childhood.
- b) 'Learning disabilities' is the widely used and accepted term in the UK. It is a term that has been used in Department of Health documents such as [Valuing people](#) (2001) and is well understood by health and social care professionals in the UK. It will therefore be used in this guideline, even though it is recognised that 'intellectual disabilities' is becoming the more widely accepted term internationally. The World Health Organization's [International statistical classification of diseases and related health problems \(10th revised edition\)](#) (ICD-10) currently uses the term 'mental retardation'. The group working on ICD-11, due to be published in 2015, has proposed that it amends this to 'intellectual developmental disorders'. [DSM-V](#), published in May 2013, replaced the DSM-IV term 'mental retardation' with 'intellectual disability'.
- c) ICD-10 defines 4 degrees of learning disability: mild (an IQ of 50–69), moderate (an IQ of 35–49), severe (an IQ of 20–34) and profound (an IQ of

less than 20). These categories have been criticised on the grounds that they omit any measure of social or adaptive functioning. In addition, it has been argued that in practice IQ scores are often uncertain in people with more severe learning disabilities. It is also widely recognised that IQ scores are not fixed throughout life, so provide only an approximate guide to intellectual ability. Accordingly, many health and social care professionals object to subdividing learning disabilities because such subdivisions create labels that are then used to describe people, often inaccurately. Moreover, there are numerous different ways of subdividing learning disabilities between and within countries (for example, in the UK 'mild' and 'moderate' learning disabilities/difficulties have different meanings in education services and in health services).

- d) Whatever subdivisions are used, a person with a milder degree of learning disability may need support in only some areas (for example, budgeting, planning and time management). The more severe a person's learning disability, the more likely the person is to have very limited communication skills and a very significantly reduced ability to learn new skills. Likewise, the more severe the learning disability, the more likely the person is to need support with daily activities such as dressing, washing, eating, and mobility. It is widely agreed that it is important to treat each person as an individual, with their own specific needs, and it is recognised that a broad and detailed assessment of needs is essential. This may include assessment of communication skills, which may well be important when there is behaviour that challenges.
- e) Learning disabilities are pervasive and are different from specific learning difficulties such as dyslexia, which do not affect intellectual ability.
- f) Some people with learning disabilities display behaviour that challenges. 'Behaviour that challenges' describes actions that often result from the interaction between individual and environmental factors. It includes aggression toward others, self-injury, stereotypic behaviour (such as rocking or hand flapping), disruptive or destructive behaviour and withdrawn behaviour. It can also include violence, arson or sexual abuse, thereby

bringing the person into contact with the criminal justice system. The most widely used definition of such behaviour is ‘culturally abnormal behaviour(s) of such intensity, frequency or duration that the physical safety of the person or others is likely to be placed in serious jeopardy, or behaviour which is likely to seriously limit use, or result in the person being denied access to, ordinary community facilities’<sup>a</sup>. Such behaviours increase the likelihood that restrictive and aversive management strategies will be used and can result in people being excluded from services and from ordinary community life.

- g) The terms ‘challenging behaviour’ and ‘behaviour that challenges’ are deliberately designed to remind professionals that the behaviour is a challenge to services, families and carers. Neither term is intended to be a diagnosis. The behaviour may appear in some environments and not others, and the same behaviour may be considered challenging in some settings or cultures but not in others. ‘Challenging behaviour’ or ‘behaviour that challenges’ can therefore be seen as a socially constructed concept that is the product of individual and environmental factors interacting. In order for behaviour to be considered ‘challenging’, it is necessary to take account of the environment in which it is occurring, its impact on others, and the capability of the staff/carers to support the person in that environment. Nevertheless, if such behaviour has serious consequences for the person or for other people, it is likely to be considered challenging in most settings in which it occurs.
- h) Behaviour that challenges is relatively common among people with learning disabilities, although the criteria used to define it affect estimates of prevalence. Prevalence rates of 5–15% have been reported in people who are in contact with educational, health or social care services for people with learning disabilities. Substantially higher rates (30–40%) are found in people with learning disabilities who live in mental health hospitals than in those who live in the community.

---

<sup>a</sup> Emerson E. Challenging behaviour: analysis and Intervention in people with learning disabilities. Second edition. Cambridge: Cambridge University Press; 2001.

- i) Behaviour that challenges has been found to correlate with severity of learning disabilities, with a general trend toward an increased prevalence of such behaviour in people with more severe learning disabilities. This is not to say that behaviour that challenges never occurs in people with mild learning disabilities, but is known to be less common among this group (although when it does occur it can bring the person into contact with the criminal justice system). People with profound and multiple learning disabilities, who often have serious physical disabilities, may not be physically able to show some behaviours that challenge but may still show self-injurious behaviour.
- j) Prevalence rates for behaviour that challenges in people with learning disabilities have also been found to be sensitive to age. The highest rates are observed during late adolescence (which may result from the difficulties experienced in transitions between services), falling to lower levels in later adulthood. Increases in the number of people living longer who acquire dementia may affect this pattern in the future.
- k) There are likely to be a number of underlying factors that contribute to the likelihood of behaviour that challenges for people with learning disabilities, including communication difficulties, sensory impairments, sensory processing difficulties, physical or mental health problems, emotional difficulties, neuropsychiatric disorders, pervasive developmental disorders, phenotype-related behaviours, abuse, psychological trauma and attachment difficulties.
- l) Behaviour that challenges also results from environmental factors (including social, physical and emotional environmental factors). In particular, the social environment has a major effect on rates of behaviour that challenges, and if people are cared for in environments that are inadequate in some way (for example, that do not respond well to their needs because of staff knowledge, training, awareness or attitudes), behaviour that challenges is likely to develop. Carers or staff can influence the occurrence of behaviour that challenges by providing or removing social attention and by presenting or removing demands and physical objects. Many other aspects of the environment are also known to have a major effect on behaviour that

challenges, for example: neglect, abuse, quality of social interaction, lack of meaningful occupation, lack of sensory input, lack of choice, excessive noise, and crowded, barren, unresponsive and unpredictable environments.

- m) The factors that contribute to the likelihood of behaviour that challenges for any one person are likely to be multiple and to involve physical, emotional and social environmental factors. Thorough assessments of the person and their environment are needed and functional analyses are likely to be useful to identify the relevant factors. Interventions are typically based on a formulation of the relevant factors for each person and may involve intervening at multiple levels (including at the physical, emotional and social environmental levels).
- n) Behaviour that challenges affects the quality of life of the person and their family and carers. In the most extreme instances it may become difficult to take the person out of their home and into the community. This means the person may be living in a restrictive environment. Other people may be placed in restrictive environments to live, often for years at a time.

### **A.2.2 Current practice**

- a) Medication is the most common intervention used to manage behaviour that challenges. Although it may be effective for some people, it is considered by most professionals to be overused and there is a danger that it may simply sedate the person and lead to polypharmacy. A significant proportion of the antipsychotic medication given to people with learning disabilities is for the management of behaviour that challenges.
- b) Behavioural techniques (including applied behaviour analysis and positive behaviour support, as well as cognitive behavioural therapy) are the next most commonly used interventions to manage behaviour that challenges. Such interventions normally include communication assessments and intervention strategies. However, the research evidence shows that most people with learning disabilities do not receive evidence-based interventions for behaviour that challenges.

- c) Families provide the majority of support for most people with learning disabilities. Outside the families, the majority of support is funded by social services (for example, support for self-care, daily living, daytime activities and respite care, specialist equipment and adaptations). Most of this support is not directly provided by social services but by independent agencies (often not-for-profit agencies). Increasingly the support is provided through personal budgets. In addition, children, young people and adults may receive education services (such as special needs education services in mainstream schools and colleges, services in special schools or classes in further education colleges). People whose behaviour challenges may also use additional specialist health services, which tend to be provided and organised by community teams. For children and young people these services are usually embedded in child and adolescent mental health services teams, although many families report that services from these teams are variable. For adults, the specialist services are usually provided by community learning disabilities teams. The transition from child to adult services is often badly managed, as are other transitions (for example, to services for older people). Services are often lacking for adults with a mild learning disability who may have significant behaviour that challenges but are otherwise relatively able, because they may fall outside the Fair Access to Care Services criteria used by social services and the criteria used by the NHS.
- d) In terms of living situations, people with learning disabilities whose behaviour challenges may be supported at home with their families, in residential services of various kinds (including residential special schools and residential services for adults) or in homes with their own tenancies (when adults), sometimes with the support of specialist teams. Severe behaviour that challenges is a common reason for long-term placement in residential special schools, assessment and treatment units or other settings. These are often located outside the person's area, sometimes hundreds of miles away. Such services may be run by independent agencies or by the NHS.

### **A.3 The guideline**

The guideline development process is described in detail on the NICE website (see section 6, 'Further information').



This scope defines what the guideline will (and will not) examine, and what the guideline developers will consider. The scope is based on the referral from the Department of Health.

The areas that will be addressed by the guideline are described in the following sections.

## **A.4 Population**

### **A.4.1 Groups that will be covered**

- a) Children, young people and adults with mild, moderate, severe or profound learning disabilities and behaviour that challenges, and their families and carers.
- b) Special consideration will be given with regard to a number of equality issues. Please see equality impact assessment form – scoping for further details.

### **A.4.2 Care setting**

- a) The guideline will cover the care and shared care provided or commissioned by health and social care, in whatever care setting the person resides.

## **A.5 Management and support**

### **A.5.1 Key issues that will be covered**

- a) Anticipating and preventing behaviour that challenges in children, young people and adults with learning disabilities, including:
  - identification of those at risk of developing behaviour that challenges
  - methods and tools for personal assessment (including assessment of sensory deficits, sensory processing disorders, physical health status, communication needs, emotional needs, mental health needs)
  - assessment of environmental factors, including the physical environment, the social environment, parent, carers and staff attitudes, skills and staff competence
  - interventions to prevent the development of behaviour that challenges.

- b) Assessment of children, young people and adults with learning disabilities who have already developed behaviour that challenges, including:
- methods and tools for assessment including assessment of sensory deficits, sensory processing disorders, physical health status, communication needs, emotional needs and mental health needs, and individual and environmental risk factors
  - assessment of environmental factors, including the physical environment, the social environment, parent, carers and staff attitudes, skills and staff competence
  - functional assessment (including functional analysis) and formulation
  - assessment of staff/carer stress and attributes that contribute to their capacity to support the person.
- c) Interventions to reduce and manage behaviour that challenges, including:
- environmental changes (including physical and social environments)
  - psychosocial interventions (including a broad range of therapies, such as communication interventions, applied behaviour analysis, positive behaviour support and cognitive behavioural therapy) for the short- and long-term reduction and management of behaviour that challenges
  - pharmacological interventions for the short- and long-term reduction and management of behaviour that challenges
- Note that guideline recommendations will normally fall within licensed indications; exceptionally, and only if clearly supported by evidence, use outside a licensed indication may be recommended. The guideline will assume that prescribers will use a drug's summary of product characteristics to inform decisions made with individual service users.*
- interventions aimed at reducing health risks and increasing an individual's understanding of their physical illness or mental health problems, and thereby possibly reducing the contribution of untreated physical illness to the development and maintenance of behaviour that challenges
  - interventions aimed at potentially offending behaviour

- reactive strategies, including safe and ethical use of restrictive interventions, such as physical restraint, mechanical restraint, confinement, containment and seclusion, and the alternatives to these.
- d) Training or education needed to allow health and social care professionals, paid carers and families to provide good-quality services and carry out all the above interventions if these are evidence based.
- e) Transitions between services
- f) Interventions and support for family and carers (including paid carers) which aim to improve the health and well-being of the family and carers
- g) Strategies to engage family and carers as a resource in the design, implementation and monitoring of interventions for the person with a learning disability.

## **A.6 Issues that will not be covered**

- a) Management of coexisting conditions, unless these affect interventions, management or support for people with learning disabilities and behaviour that challenges.

## **A.7 Main outcomes**

- a) Severity, frequency and duration of the targeted behaviour that challenges.
- b) Adaptive functioning, including communication skills.
- c) Mental and psychological health outcomes (such as mood and anxiety).
- d) Quality of life.
- e) Service user and carer satisfaction.
- f) Effects on carer stress and resilience.
- g) Adverse effects on other people with learning disabilities.
- h) Rates of seclusion.
- i) Rates of manual restraint.

- j) Use of psychoactive medication.
- k) Premature death.
- l) Rates of placement breakdown.
- m) Use of inpatient placements (including out-of-area placements).

## **A.8 Economic aspects**

Developers will take into account both clinical and cost effectiveness when making recommendations involving a choice between alternative interventions. A review of the economic evidence will be conducted and analyses will be carried out as appropriate. The preferred unit of effectiveness is the quality-adjusted life year (QALY) but a different unit of effectiveness may be used depending on the availability of appropriate clinical and utility data for people with learning disability and behaviour that challenges. The costs considered will usually be only from an NHS and personal social services (PSS) perspective, although economic analyses will attempt to incorporate wider costs associated with the care of people with learning disabilities and behaviour that challenges if appropriate cost data are available. Further detail on the methods can be found in 'The guidelines manual' (see 'Further information').

## **A.9 Status**

### **A.9.1 Scope**

This is the final scope.

### **A.9.2 Timing**

The development of the guideline recommendations will begin in July 2013.

## **A.10 Related NICE guidance**

- [Autism in adults](#). NICE clinical guideline 142 (2012).
- [The epilepsies](#). NICE clinical guideline 137 (2012).
- [Service user experience in adult mental health](#). NICE clinical guidance 136 (2011).
- [Self-harm: longer-term management](#). NICE clinical guideline 133 (2011).
- [Autism diagnosis in children and young people](#). NICE clinical guideline 128 (2011).
- [Dementia](#). NICE clinical guideline 42 (2006).
- [Self-harm](#). NICE clinical guideline 16 (2004).

### **A.10.1 Guidance under development**

NICE is currently developing the following related guidance (details available from the NICE website):

- Autism: the management and support of children and young people on the autism spectrum. NICE clinical guideline. Publication expected August 2013.
- Violence and aggression. NICE clinical guideline. Publication expected December 2014.

### **A.11 Further information**

Information on the guideline development process is provided in the following documents, available from the NICE website:

- [‘How NICE clinical guidelines are developed: an overview for stakeholders the public and the NHS’](#)
- [‘The guidelines manual’](#).

Information on the progress of the guideline will also be available from the [NICE website](#).

## Appendix B: Declarations of interests by Guideline Development Group members

With a range of practical experience relevant to behaviour that challenges in people with learning disabilities in the Guideline Development Group (GDG), members were appointed because of their understanding and expertise in healthcare for people with behaviour that challenges in people with learning disabilities and support for their families and carers, including: scientific issues; health research; the delivery and receipt of healthcare, along with the work of the healthcare industry; and the role of professional organisations and organisations for people with learning disabilities and behaviour that challenges and their families and carers.

To minimise and manage any potential conflicts of interest, and to avoid any public concern that commercial or other financial interests have affected the work of the GDG and influenced guidance, members of the GDG must declare as a matter of public record any interests held by themselves or their families which fall under specified categories (see below). These categories include any relationships they have with the healthcare industries, professional organisations and organisations for people with learning disabilities and behaviour that challenges and their families/carers.

Individuals invited to join the GDG were asked to declare their interests before being appointed. To allow the management of any potential conflicts of interest that might arise during the development of the guideline, GDG members were also asked to declare their interests at each GDG meeting throughout the guideline development process. The interests of all the members of the GDG are listed below, including interests declared prior to appointment and during the guideline development process.

Please note that the Challenging Behaviour and Learning Disabilities Guideline Development Group was recruited under NICE's 2007 declaration of interests policy.

### Categories of interest to be written in third person

- Paid employment
- Personal pecuniary interest: financial payments or other benefits from either the manufacturer or the owner of the product or service under consideration in this guideline, or the industry or sector from which the product or service comes. This includes holding a directorship or other paid position; carrying out consultancy or fee paid work; having shareholdings or other beneficial interests; receiving expenses and hospitality over and above what would be reasonably expected to attend meetings and conferences.
- Personal family interest: financial payments or other benefits from the healthcare industry that were received by a member of your family.
- Non-personal pecuniary interest: financial payments or other benefits received by the GDG member's organisation or department, but where the GDG member has not personally received payment, including fellowships and other support provided by the healthcare industry. This includes a grant or fellowship or other payment to sponsor a post, or contribute to the running costs of the department; commissioning of research or other work; contracts with, or grants from, NICE.
- Personal non-pecuniary interest: these include, but are not limited to, clear opinions or public statements you have made about challenging behaviour and learning disabilities, holding office in a professional organisation or advocacy group with a direct interest in challenging behaviour and learning disabilities, other reputational risks relevant to challenging behaviour and learning disabilities.

<b>Declarations of interest</b>	
<b>Glynis Murphy (Chair)</b>	
Employment	Professor of Clinical Psychology and Disability, Co-Director of the Tizard Centre, University of Kent
Personal pecuniary interest	<p>Until October 2012, employed (part-time) by the NHS.</p> <p>Conduct consultancy for NHS police and lawyers, normally contracted for through the University of Kent Enterprise department, and paid for through my University of Kent salary.</p> <p>Co-editor, Journal of Applied Research in Intellectual Disability.</p> <p>Member, Care Quality Commission panel.</p> <p>Member, National Offender Management Service accreditation panel.</p>
Personal family interest	None
Non-personal pecuniary interest	<p>Co-director, Tizard Centre, in receipt of grants (National Institute for Health Research/charities).</p> <p>Tizard Centre, training for staff from Learning Disabilities.</p> <p>Tizard Centre research grant; treatment of sexually abusive behaviour in young people with a learning disability.</p>
Personal non-pecuniary interest	<p>Conducted own research into challenging behaviour.</p> <p>Chair, Sexual Offender Treatment South East Collaborative – Intellectual Disability.</p> <p>Immediate Past President International Association for the Scientific Study of Intellectual and Developmental Disabilities.</p>
Actions taken	None
<b>Steve Pilling (Facilitator)</b>	
Employment	Director, NCCMH
Personal pecuniary interest	None
Personal family interest	<p>Medical Research Council, research funding looking at psilocybin.</p> <p>Grant from National Alliance for Research on Schizophrenia and Depression to look at transcranial direct-current stimulation in treatment of depression.</p>
Non-personal pecuniary interest	None
Personal non-pecuniary interest	None

Actions taken	None
<b>David Allen</b>	
Employment	Clinical Director, Positive Response Training and Consultancy and Professor, Tizard Centre, University of Kent.
Personal pecuniary interest	<p>Positive Response Training and Consultancy provides training to health and social care staff and families supporting people with learning disabilities and challenging behaviour. It uses an over-arching positive behaviour support model and provides training in both proactive, preventative strategies and reactive strategies. The physical intervention training component of the latter is accredited by the British Institute of Learning Disabilities.</p> <p>Editor of International Journal of Positive Behavioural Support.</p> <p>Collaborator in randomised control trial of Training in Positive Behavioural Support (Hassiotis, 2013).</p> <p>Joint applicant, Reduction in Anti-psychotic Medication in People with Learning Disability and Challenging Behaviour (Kerr, Felce 2013).</p>
Personal family interest	None
Non-personal pecuniary interest	Honorary Professor, University of Kent.
Personal non-pecuniary interest	<p>Member of various working groups set up as part of Positive and Safe Programme.</p> <p>Member of Positive and Safe Programme Board.</p> <p>Member of group that recently produced competence framework for positive behaviour support.</p>
Actions taken	None
<b>Katherine Andrea</b>	
Employment	Senior Project Manager, NCCMH
Personal pecuniary interest	None
Personal family interest	None
Non-personal pecuniary interest	None
Personal non-pecuniary interest	None
Actions taken	None
<b>David Branford</b>	
Employment	Retired
Personal pecuniary interest	<p>Development of guideline on dysphagia in learning disabilities supported by Rosemont Pharmaceuticals.</p> <p>Opinion on lisdexamphetamine supported by Pharmacy management.</p>



	Opinion on lurasidone supported by Sunovion Pharmaceuticals.
Personal family interest	None
Non-personal pecuniary interest	<p>PhD on antipsychotic drugs in learning disabilities.</p> <p>Chairman of the English Pharmacy Board of the Royal Pharmaceutical Society.</p> <p>Elected member of the College of Mental Health Pharmacy.</p> <p>Editor of Frith prescribing guidelines for adults with learning disabilities (no financial interest).</p>
Personal non-pecuniary interest	None
Actions taken	None
<b>Alick Bush</b>	
Employment	Lead Psychologist, St Andrews Healthcare
Personal pecuniary interest	Employed 0.6 whole time equivalent by St Andrews Healthcare, a charity that provides inpatient care to adults with learning disabilities and autism. Provides a clinical psychology service to patients in the hospital.
Personal family interest	None
Non-personal pecuniary interest	None
Personal non-pecuniary interest	<p>Policy lead, British Psychological Society Faculty of Learning Disabilities – promoted the use of predominantly psychosocial interventions for adults who challenge services, including positive behaviour support.</p> <p>Until December 2014, Chair of the Learning Disabilities Professional Senate – an alliance of the professional bodies that provide support to people with learning disabilities. Representative of the Professional Senate on the Learning Disability Programme Board. On a range of sub-committees and working groups that are responsible for delivering the Transforming Care action plan following the Winterbourne View review. This includes being a member of the Expert Advisory Group on the promotion of positive behaviour support.</p> <p>Co-editor of 'Challenging Behaviour: a unified approach' (London: Royal College of Psychiatrists, British Psychological Society and Royal College of Speech and Language Therapists; March 2007).</p> <p>Acted as a special advisor on a Care Quality Commission inspection.</p>
Actions taken	None
<b>Carole Buckley</b>	
Employment	General Practitioner, The Old School Surgery.
Personal pecuniary interest	Non-executive Director GP Care (UK) Ltd: Private provider of NHS services to patients.

	Chair, St Mathias holdings Ltd: Practice based pharmacy offering services to residential care homes.
Personal family interest	None
Non-personal pecuniary interest	<p>Member, Royal College of General Practitioners intellectual disability professional network.</p> <p>Clinical Champion for Autism by the Royal College of General Practitioners.</p> <p>Joint recipient of a grant from Bristol University to implement focus groups for service users and carers in order to inform GP practice.</p> <p>Grant from the Academic Health Science Network South West to hold a conference in Taunton 19/11/14 for commissioners and providers of autism services.</p>
Personal non-pecuniary interest	None
Actions taken	None
<b>Vivien Cooper</b>	
Employment	Carer representative/Chief Executive Officer, The Challenging Behaviour Foundation.
Personal pecuniary interest	None
Personal family interest	None
Non-personal pecuniary interest	None
Personal non-pecuniary interest	<p>Member, Transforming Care Assurance Board (formerly Winterbourne View Joint Improvement Board).</p> <p>Member, Engagement Steering Group for Joint Improvement team (from June 2014 formerly Chair).</p> <p>Respond Steering Group for support for Winterbourne View families.</p> <p>Department of Health Advocacy Group.</p> <p>Department of Health Medication Collaborative Group, Steering Group.</p> <p>Care Quality Commission Learning Disability Advisory Group.</p> <p>Hassiotis University College London Positive Behaviour Support Research Group.</p> <p>Tizard E-Pats Fellowship Steering Group.</p> <p>Chair, Challenging Behaviour National Strategy Group.</p> <p>Member, Council for Disabled Children Restrictive Physical Intervention Steering Group.</p>

	Member, Department of Health Winterbourne View Capital Funding Panel.
	Member, Learning Disabilities Professional Senate.
	Member, School for Social Care Research User Carer Practitioner Reference Group.
	Member, Learning Disabilities Voluntary and Community Sectors Steering Group (July – November 2014).
	Member, Children and Young People Collaborative Steering Group.
Actions taken	None
<b>Jo Dwyer</b>	
Employment	Clinical Specialist Occupational Therapist, Lewisham Team for Adults With Learning Disabilities, Guys and St Thomas's NHS Foundation Trust
Personal pecuniary interest	None
Personal family interest	None
Non-personal pecuniary interest	None
Personal non-pecuniary interest	None
Actions taken	None
<b>David Glynn</b>	
Employment	Health Economist, NCCMH (September 2014 onwards)
Personal pecuniary interest	None
Personal family interest	None
Non-personal pecuniary interest	None
Personal non-pecuniary interest	None
Actions taken	None
<b>Bronwyn Harrison</b>	
Employment	Systematic Reviewer, NCCMH
Personal pecuniary interest	None
Personal family interest	None
Non-personal pecuniary interest	None
Personal non-pecuniary interest	None
Actions taken	None
<b>Angela Hassiotis</b>	
Employment	Professor, University College London Honorary Consultant Psychiatrist, Camden & Islington Foundation Trust
Personal pecuniary interest	None
Personal family interest	None

Non-personal pecuniary interest	<p>Current National Institute for Health Research Health Technology Assessment grant on the evaluation of positive behaviour support.</p> <p>Honoraria received by Novartis for consultancy on treatments for Fragile X syndrome.</p> <p>Other research funding (National Institute for Health Research – Research for Patient Benefit).</p> <p>Associate Editor, Journal of Policy and Practice in Intellectual and Developmental Disabilities.</p> <p>Associate Editor, Journal of Applied Research in Intellectual Disabilities.</p> <p>Editorial Board of Advances in Mental Health Intellectual Disabilities.</p> <p>Treasurer, Faculty of the Psychiatry of Intellectual Disabilities.</p> <p>Honoraria for lectures.</p> <p>Conducting a study looking at music therapy and people with a learning disability. Co-applicant on a National Institute for Health Research Health Technology Assessment funded study, evaluating music therapy for children with autism.</p>
Personal non-pecuniary interest	Published on challenging behaviour for some years following research carried out under own supervision.
Actions taken	None
<b>Phil Howell</b>	
Employment	Physical Intervention Accreditation Scheme Manager and positive behaviour support Consultant, British Institute of Learning Disabilities.
Personal pecuniary interest	None
Personal family interest	None
Non-personal pecuniary interest	None
Personal non-pecuniary interest	None
Actions taken	None
<b>Simon Jones</b>	
Employment	Head of Behavioural Support, Care UK
Personal pecuniary interest	Positive Range of Options to Avoid Crisis and use Therapy, Strategies for Crisis Intervention and Prevention (PROACT-SCIPr-UK) trainer, which is a British Institute of Learning Disabilities accredited physical intervention methodology.
Personal family interest	None

Non-personal pecuniary interest	None
Personal non-pecuniary interest	None
Actions taken	None
<b>Elena Marcus</b>	
Employment	Research Assistant, NCCMH (August 2014 onwards)
Personal pecuniary interest	None
Personal family interest	None
Non-personal pecuniary interest	None
Personal non-pecuniary interest	None
Actions taken	None
<b>Ifigeneia Mavranzouli</b>	
Employment	Senior Health Economist, NCCMH
Personal pecuniary interest	None
Personal family interest	None
Non-personal pecuniary interest	None
Personal non-pecuniary interest	None
Actions taken	None
<b>Richard Mills</b>	
Personal pecuniary interest	<p>Research Director at Research Autism.</p> <p>AT-Autism (Autism Training Ltd) – Associate.</p> <p>London Borough of Redbridge – training in clinical interviewing techniques for Approved Mental Health Professionals when working with individuals with Asperger’s syndrome and autism in conjunction with AT-Autism.</p> <p>Laskaridou Foundation Athens, Greece – Mentor/teacher programme for children with autism and challenging behaviour in conjunction with AT-Autism.</p> <p>Associate, the Tizard Centre, University of Kent at Canterbury – Curriculum development Social Work Training.</p>
Personal family interest	None
Non-personal pecuniary interest	<p>Joint recipient of a grant from Bristol University to implement focus groups for service users and carers in order to inform GP practice.</p> <p>Staff training Jersey Employment Trust through Research Autism.</p>
Personal non-pecuniary interest	<p>Fellow, Royal Society of Medicine.</p> <p>Member, International Society for Autism Research,</p> <p>Honorary Research Fellow at the Department of Psychology, University of Bath.</p>

	Senior Research Fellow, Bond University, Queensland, Australia.
	Member, Northern Ireland Advisory Committee on Autism Research.
Actions taken	None
<b>David Newton</b>	
Employment	Team Manager, Adult Safeguarding Quality Assurance Team, Adult Social Care Directorate, Nottingham City Council.
Personal pecuniary interest	Employed by a local authority; involves liaison with local authority and local clinical commissioning group contracts and commissioning groups and quality assurance. Some incidental input into local authority core contract and service specification content.
Personal family interest	None
Non-personal pecuniary interest	None
Personal non-pecuniary interest	None
Actions taken	None
<b>Steve Noone</b>	
Employment	Consultant Clinical Psychologist, Northumberland, Tyne and Wear Foundation NHS Trust.
Personal pecuniary interest	None
Personal family interest	None
Non-personal pecuniary interest	None
Personal non-pecuniary interest	None
Actions taken	None
<b>Cheryl Palmer</b>	
Employment	Research Assistant, NCCMH.
Personal pecuniary interest	None
Personal family interest	None
Non-personal pecuniary interest	None
Personal non-pecuniary interest	None
Actions taken	None
<b>Phil Perkins</b>	
Employment	Senior Community Learning Disability Nurse for Children and Young People, Surrey and Borders Partnership NHS Foundation Trust.
Personal pecuniary interest	None
Personal family interest	None
Non-personal pecuniary interest	None
Personal non-pecuniary interest	None
Actions taken	None

<b>Victoria Slonims</b>	
Employment	Senior Consultant Speech and Language Therapist; Honorary Senior Lecturer, Evelina Children's Hospital, Guy's and St Thomas' NHS Foundation Trust.
Personal pecuniary interest	Autism Diagnostic Observation Schedule trainer.
Personal family interest	None
Non-personal pecuniary interest	None
Personal non-pecuniary interest	None
Actions taken	None
<b>Clare Taylor</b>	
Employment	Senior Editor, NCCMH.
Personal pecuniary interest	None
Personal family interest	None
Non-personal pecuniary interest	None
Personal non-pecuniary interest	None
Actions taken	None
<b>Craig Whittington</b>	
Employment	Associate Director Associate Director (Clinical Effectiveness)/Senior Systematic Reviewer, NCCMH (September 2014 onwards).
Personal pecuniary interest	Member of the scientific steering committee for a US company Doctor Evidence Llc. Doctor Evidence is, a specialty software platform and services company with clients from across the healthcare ecosystem. The role includes a share option (3 year vesting) and a meeting stipend.
Personal family interest	None
Non-personal pecuniary interest	None
Personal non-pecuniary interest	None
Actions taken	None
<b>Keith Wyncoll</b>	
Employment	Carer representative
Personal pecuniary interest	Occasional trainer, The Challenging Behaviour Foundation.  Lay member, NHS England Patient and Public Voice Assurance Group – Specialised Commissioning.
Personal family interest	None
Non-personal pecuniary interest	None
Personal non-pecuniary interest	None
Actions taken	None

## **Appendix C: Special advisors to the Guideline Development Group**

Those who acted as advisors on specialist topics or have contributed to the process by meeting the Guideline Development Group:

- Gemma Griffiths, Bangor University
- Mieke Heyvaert, Katholieke Universiteit Leuven.



## **Appendix D: Stakeholders who submitted comments in response to the consultation draft of the guideline**

- 2gether NHSFT
- 5 Boroughs partnership NHSFT
- ABA4All
- Abertawe Bro Morgannwg University Health Board
- ABMU Health Board
- Association for Cognitive Analytic Therapy
- Betsi Cadwaladr University Health Board
- Birmingham Community Healthcare NHS Trust
- Black Country Partnership NHSFT
- British Academy of Childhood Disability
- British Psychological Society
- Calderstones Partnership NHS Trust
- CALM
- Certitude
- Challenging Behaviour Foundation
- College of Mental Health Pharmacy
- College of Occupational Therapists
- Contact a Family
- Department of Health
- Department of Health, Social Services and Public Safety – Northern Ireland
- Derbyshire Healthcare NHSFT
- Havencare
- HQT Diagnostics
- Imp
- Kent and Medway NHS Trust
- Kent Community Health NHS Trust
- Lancashire Care NHSFT
- Leeds & York Partnership NHS Trust
- Medicines and prescribing centre
- National Family Carer Network
- NHS Protect
- Nottinghamshire Healthcare NHS Trust
- Optical Confederation
- Oxleas NHSFT
- PBS4
- Public Health England

- Quality Standards
- Queen's University Belfast
- Real Life Options
- Rotherham Doncaster & South Humber NHSFT
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Paediatrics and Child Health
- Royal College of Psychiatrists
- Royal Mencap Society
- Sirona Care & Health CIC
- Social Care
- South Staffordshire and Shropshire Healthcare NHSFT
- Southern Health NHSFT
- St Oswald's Hospice
- Surrey and Borders Partnership NHSFT
- Sutton Council
- Tees Esk & Wear Valleys NHSFT
- The Disabilities Trust
- UK Society for Behaviour Analysis
- Ulster University
- United Response
- University of Warwick


## **Appendix E: Researchers contacted to request information about unpublished or soon-to-be published studies**

- Dr Ahmed
- Dr Akhondzadeh
- Dr Aman
- Dr Amminger
- Dr Amore
- Dr Anderson
- Dr Appleton
- Dr Bagner
- Dr Balthazer
- Dr Bent
- Dr Bilgin
- Dr Braam
- Dr Breau
- Dr Brightman
- Dr Camilleri
- Dr Carr
- Dr Chadwick
- Dr Chan
- Dr Coppola
- Dr Cortesi
- Dr Craft
- Dr Davis
- Dr Diament
- Dr Dodge
- Dr Durand
- Dr Dykens
- Dr Escalona
- Professor Felce
- Dr Feinberg
- Dr Feldman
- Dr Ferraioli
- Dr Fitzgerald
- Dr Gagiano
- Dr Gammon
- Dr Garstang
- Dr Gençöz
- Dr Ghanizadeh
- Dr Gray
- Dr Greaves
- Dr Griffin
- Dr Griffith
- Dr Hagiliassis
- Dr Hand
- Dr Hardan
- Dr Hassiotis
- Dr Hellings
- Dr Heyvaert
- Dr Hollander
- Dr Hudson
- Dr Izmeth
- Dr Jan
- Dr Jocelyn
- Dr Johnson
- Dr Jones
- Dr Kent
- Dr Kirkham
- Dr Kleefman
- Dr Knapp
- Dr Kwako
- Dr Larson
- Dr Lennox
- Dr Leung
- Dr Lindsay
- Dr Lofthouse
- Dr Lundqvist
- Dr Lynch
- Ms Lemmi
- Dr Malt
- Dr Marcus
- Dr Martin
- Dr McArthur
- Dr McIntyre
- Dr McPhail
- Dr Montgomery

- Dr Morrissey
- Dr Moss
- Dr Neece
- Dr Nezu
- Dr Nixon
- Dr O'Callaghan
- Dr Oliva
- Dr Owen
- Dr Packman
- Dr Piazza
- Dr Piravej
- Dr Plant
- Dr Prieto-Bayard
- Dr Quinsey
- Dr Roberts
- Dr Rojahn
- Dr Roux
- Dr Scahill
- Dr Sallows
- Dr Schuiringa
- Dr Schultz
- Dr Shapiro
- Dr Shea
- Dr Sigafos
- Dr Singer
- Dr Singh
- Dr Smith
- Dr Snowden
- Dr Sofronoff
- Dr Stores
- Dr Strain
- Dr Synder
- Dr Taffe
- Dr Taylor
- Dr Tonge
- Dr Turk
- Dr Tyrer
- Dr Vaisanen
- Dr Van Bellinghen
- Dr Van Den Berg
- Dr Vanden Borre
- Dr Verbrugge
- Dr Vohra
- Dr Wasdell
- Dr Weir
- Dr White
- Dr Whittingham
- Dr Wiggs
- Dr Wigram
- Dr Wilcox
- Dr Willner
- Dr Wong
- Dr Wright
- Dr Yildirim
- Dr Zarccone

# Appendix F: Analytic framework, review questions and review protocols

## F.1 Analytical framework



## F.2 Review questions

RQ	Review question
1.1	In people with a learning disability, what are the circumstances, risk factors and antecedents associated with the development of behaviour that challenges?
1.2	In people with a learning disability, what is the utility of methods and tools used to assess the circumstances, risk factors and antecedents associated with the development of behaviour that challenges (including assessment of sensory deficits, sensory processing disorders, physical health status, communication needs, emotional needs, mental health needs, and environmental factors)?
2.1	In people with a learning disability, what are the key components of, and the most effective structure for, an assessment of the behaviour that challenges across a range of settings?  To answer this question, consideration should be given to: <ul style="list-style-type: none"> <li>• methods of assessment (including functional analysis)</li> <li>• formal assessment tools/psychological instruments (including risk assessment)</li> <li>• biological and physical health measures</li> </ul>
2.2	In people with a learning disability and behaviour that challenges, what is the utility of methods and tools for assessment?
2.3	In carers of people with a learning disability and behaviour that challenges, what is the utility of methods used to assess and monitor their capacity to support the person?  To answer this question, consideration should be given to the: <ul style="list-style-type: none"> <li>• identification of appropriate carers</li> <li>• assessment of carers skills and capacity</li> </ul>
3.1	In people with a learning disability, what are the benefits and potential harms of interventions (including early intervention) aimed at preventing the development of behaviour that challenges?
3.2	In people with a learning disability, and their carers, what are the benefits and potential harms of interventions aimed at reducing health risks and increasing understanding of physical illness or mental health problems in relation to the prevention or management of the behaviour that challenges?
4.1	In people with a learning disability and behaviour that challenges, what are the benefits and potential harms associated with environmental changes (including the physical and social environments) aimed at reducing and managing behaviour that challenges (including potentially offending behaviour)?
4.2	In people with a learning disability and behaviour that challenges, what are the benefits and potential harms associated with psychosocial interventions (including a broad range of therapies, such as communication interventions, applied behaviour analysis, positive behaviour support and cognitive behavioural therapy) aimed at reducing and managing behaviour that challenges (including potentially offending behaviour)?
4.3	In people with a learning disability and behaviour that challenges, what are the benefits and potential harms associated with pharmacological interventions aimed at reducing and managing behaviour that challenges (including potentially offending behaviour)?
4.4	In people with a learning disability and behaviour that challenges, what are the benefits and potential harms of 'reactive strategies' (including physical restraint, mechanical restraint, confinement, and containment and seclusion) aimed at managing behaviour that challenges?
5.1	In family and carers of people with a learning disability and behaviour that challenges, what are the benefits and potential harms of interventions aimed at improving their health and well-being?
5.2	What are the benefits and potential harms of strategies aimed at engaging the family and carers of people with a learning disability and challenging behaviour as a resource in the

RQ	Review question
	design, implementation and monitoring of interventions for the person with a learning disability and challenging behaviour?
6.1	What are the benefits and potential to allow health and social care professionals and carers to provide good-quality services and carry out evidence based interventions designed to reduce or manage behaviour that challenges in people with a learning disability?
7.1	<p>In people with a learning disability and behaviour that challenges, what are the effective models for transition between services (for example child-adult, adult-older adult, NHS-social care/residential)?</p> <p>To answer this question, consideration should be given to:</p> <ul style="list-style-type: none"> <li>• the structure, design and delivery of care pathways</li> <li>• the nature and duration of support provided during transition.</li> </ul>
8.1	In people with a learning disability and behaviour that challenges, what are their experiences of having a learning disability and behaviour that challenges, of access to services, and of treatment?
8.2	For the family carers of people with a learning disability and behaviour that challenges, what are their experiences of caring for people with a learning disability and behaviour that challenges, and what support is available for families, partners and carers?

## F.3 Review protocols

### F.3.1 Topic: Anticipation and identification

Item No.	Item	Details
1.	Review question(s)	<p>RQ1.1: In people with a learning disability, what are the circumstances, risk factors and antecedents associated with the development of behaviour that challenges?</p> <p>RQ1.2: In people with a learning disability, what is the utility of methods and tools used to assess the circumstances, risk factors and antecedents associated with the development of behaviour that challenges (including assessment of sensory deficits, sensory processing disorders, physical health status, communication needs, emotional needs, environmental factors and mental health needs)?</p>
2.	Sub-question(s)	–
3.	Searches	<p>RQ1.1 (updates McClintock et al 2003) Major bibliographic databases: Embase (2003 to October 2014), MEDLINE/PreMEDLINE (2003 to October 2014), PsycINFO (2003 to October 2014)</p> <p>RQ1.2: Major bibliographic databases: Embase (inception to October 2014), MEDLINE/PreMEDLINE (inception to October 2014), PsycINFO (inception to October 2014)</p> <p><i>Note. Conference abstracts will be assessed for eligibility and potentially eligible studies will be checked to determine if they have been published or made available in a full report.</i></p> <p>Other resources of evidence:</p> <ul style="list-style-type: none"> <li>• Reference lists of included studies</li> <li>• Registered stakeholders</li> <li>• Trial authors and drug companies</li> <li>• Trial registries (<a href="http://www.controlled-trials.com/">http://www.controlled-trials.com/</a>; <a href="https://www.clinicaltrialsregister.eu">https://www.clinicaltrialsregister.eu</a>)</li> </ul>



Item No.	Item	Details
		<ul style="list-style-type: none"> <li>• PROSPERO</li> <li>• Non-English-language papers (with English abstracts) will be assessed for eligibility and potentially eligible studies will be checked to determine if they have been published in an English-language journal. Studies that have not been published in an English-language journal will not be included in the review.</li> </ul> <p><i>Note. Unpublished data will only be included where a full trial report is available with sufficient detail to properly assess the risk of bias. Authors of unpublished evidence will be asked for permission to use such data, and will be informed that summary data from the study and the study's characteristics will be published in the full guideline.</i></p>
4.	Condition or domain being studied	<p>Challenging behaviour and learning disabilities</p> <p>Definitions: Challenging behaviour: 'Culturally abnormal behaviour(s) of such an intensity, frequency or duration that the physical safety of the person or others is likely to be placed in serious jeopardy, or behaviour which is likely to seriously limit use of, or result in the person being denied access to, ordinary community facilities'<sup>b</sup>.</p> <p>Learning disabilities: Heterogeneous conditions, but are defined by 3 core criteria: lower intellectual ability (usually defined as an IQ of less than 70), significant impairment of social or adaptive functioning and onset in childhood. This corresponds to 'mental retardation' as described in the major taxonomies DSM-IV and ICD-10.</p>
5.	Participants/population	<p>Children, young people and adults with a mild, moderate, severe or profound learning disability.</p> <p>Exclude coexisting conditions (unless these affect interventions, management or support for people with a learning disability and behaviour that challenges).</p>
6.	Intervention(s), exposure(s)	<p>Circumstances, risk factors and antecedents for challenging behaviour: Circumstance = a fact or condition connected with or relevant to an event or action Risk factor = a variable associated with an increased risk of disease/disorder Antecedent = anything that precedes another thing, especially the cause of the second thing. Methods and tools used to assess the circumstances, risk factors and antecedents associated with the development of behaviour that challenges:</p>

<sup>b</sup> Emerson E. Challenging Behaviour: Analysis and Intervention in People with Learning Disabilities. Second edition. Cambridge: Cambridge University Press; 2001.

Item No.	Item	Details
		<p>methods and tools for personal assessment (including assessment of sensory deficits, sensory processing disorders, physical health status, communication needs, emotional needs and mental health needs)</p> <p>assessment of environmental factors (including the physical environment, the social environment, parent, carers and staff attitudes, skills and staff competence)</p>
7.	Comparator(s)/control	N/A
8.	Types of study to be included initially	<p>RQ1.1: Any RQ1.2: Any</p> <p>Excluded studies that did not use instruments in English, to ensure greatest applicability to the UK.</p>
9.	Context	Care and shared care provided or commissioned by health and social care, in whatever care setting the person resides.
10.	Primary/Critical outcomes	<p>RQ1.1: Correlation between risk factor and challenging behaviour RQ1.2: Clinical utility (including sensitivity and specificity)</p> <p>Definitions</p> <p>Clinical utility: the instrument should be feasible and implementable in a routine clinical care, especially primary care. The instrument should contribute to the identification of further assessment needs and inform decisions about referral to other services.</p> <p>Psychometric data: The instrument should have established reliability and validity.</p> <p>Psychometric properties of instruments that meet inclusion criteria will be evaluated according to the following criteria:</p> <p>Reliability</p> <ul style="list-style-type: none"> <li>• Inter-rater reliability – correlation between 2 raters (<math>r \geq 0.70</math>) = relatively reliable.</li> <li>• Test-retest reliability – stability of the instrument as shown by the correlation between test scores in the same group of participants across 2 different times (<math>r \geq 0.70</math>) = relatively reliable.</li> <li>• Internal consistency – the extent to which items measure a single construct (<math>r \geq 0.70</math> or <math>\alpha \geq 0.50</math>; <math>k \geq 0.40</math>) = relatively reliable.</li> </ul> <p>Validity</p> <ul style="list-style-type: none"> <li>• Criterion validity – minimum <math>r = 0.50</math> (or some suggest 0.30 to 0.40 is more reasonable).</li> </ul>

Item No.	Item	Details
		<p>Criterion validity refers to the degree to which there is a relationship between the instrument and some other established standard of the measure of interest. There are 2 subtypes of criterion validity: (1) predictive validity (extent to which instrument scores are correlated with performance on some future criterion) and (2) concurrent validity (extent to which instrument scores are correlated with performance on a related criterion at the same time point).</p> <ul style="list-style-type: none"> <li>• Construct validity <math>r \geq 0.50</math> or discrimination index = 0.3 to 0.7. Construct validity refers to the degree to which the instrument measures the construct. Construct validity includes 2 subtypes: (1) discriminant validity (degree to which the instrument differentiates between constructs that are different, such as cases and controls) and (2) convergent validity (correlation between constructs that are similar).</li> </ul>
11.	Secondary/Important, but not critical outcomes	N/A
12.	Data extraction (selection and coding)	<p>Citations from each search will be downloaded into EndNote and duplicates removed. Records will then be screened against the eligibility criteria of the review. The unfiltered search results will be saved and retained for future potential re-analysis. All primary-level studies included after the first scan of citations will be acquired in full and re-evaluated for eligibility at the time they are being entered into a study database (standardised template created in Microsoft Excel). Eligibility will be confirmed by at least 1 member of the GDG. The GDG are experts in the topic and/or research methodology. Two researchers will extract data into the study database, comparing a sample of each other's work for reliability. Discrepancies or difficulties with coding will be resolved through discussion with members of the GDG.</p>
13.	Risk of bias (quality) assessment	The quality of individual studies will be assessed using the appropriate NICE quality assessment checklist.
14.	Strategy for data synthesis	<p>RQ1.1 Where appropriate, meta-analysis using a random-effects model will be used to combine results from similar studies.</p> <p>RQ1.2: We will conduct pooled diagnostic accuracy meta-analyses on the sensitivity and specificity of methods and tools to assess the circumstances, risk factors and antecedents associated with the development of behaviour that challenges in people with a learning disability (dependent on available data). In the absence of adequate data, a narrative review of methods and tools to assess the circumstances, risk factors and antecedents will be conducted and guided by available evidence, current practice and GDG consensus (for example, the clinical utility of the tool and psychometric data evaluating its reliability and validity).</p> <p>If existing reviews are found, the review team with advice from the GDG will assess their quality, completeness, and applicability to the NHS and to the scope of the guideline. If the GDG agree that a systematic review appropriately addresses a review question, we will search for studies conducted or published since the review was conducted, and the</p>

Item No.	Item	Details
		GDG will assess if any additional studies could affect the conclusions of the previous review. If new studies could change the conclusions, we will update the review and conduct a new analysis. If new studies could not change the conclusions of an existing review, the GDG will use the existing review to inform their recommendations.
15.	Analysis of subgroups or subsets (including sensitivity analyses)	<p>Subgroups include:</p> <p>Population: Children and young people; adults.</p> <p>Degree of learning disability: mild (an IQ of 50–69), moderate (an IQ of 35–49), severe (an IQ of 20–34) and profound (an IQ of less than 20).</p> <p>Form of challenging behaviour:</p> <p>Self-injurious behaviour (includes head-banging, scratching, pulling, eye poking, picking, grinding teeth, eating non-foodstuffs)</p> <p>Aggressive behaviour toward others (includes biting and scratching, hitting, pinching, grabbing, hair pulling, throwing objects, verbal abuse, screaming, spitting).</p> <p>Stereotyped behaviour (including repetitive movements, rocking, repetitive speech and repetitive manipulation of objects).</p> <p>Non-person directed behaviour (includes damage to property, hyperactivity, stealing, inappropriate sexualised behaviour, destruction of clothing, incontinence, lack of awareness of danger, withdrawal).</p>

### F.3.2 Topic: Monitoring and assessment

Item No.	Item	Details
1.	Review question(s)	<p>RQ2.1: In people with a learning disability, what are the key components of, and the most effective structure for, an assessment of the behaviour that challenges across a range of settings? To answer this question, consideration should be given to:</p> <p>methods of assessment (including functional analysis)</p> <p>formal assessment tools/psychological instruments (including risk assessment)</p> <p>biological and physical health measures</p> <p>RQ2.2: In people with a learning disability and behaviour that challenges, what is the utility of methods and tools for assessment?</p> <p>RQ2.3: In carers of people with a learning disability and behaviour that challenges, what is the utility of methods used to assess and monitor their capacity to support the person? To answer this question, consideration should be given to the:</p>

Item No.	Item	Details
		<p>identification of appropriate carers assessment of carers skills and capacity</p>
2.	Sub-question(s)	RQ#:
3.	Searches	<p>RQ2.1: N/A; GDG consensus-based</p> <p>RQ2.2, 2.3: Major bibliographic databases: Embase (inception to October 2014), MEDLINE/PreMEDLINE (inception to October 2014), PsycINFO (inception to October 2014)</p> <p><i>Note. Conference abstracts will be assessed for eligibility and potentially eligible studies will be checked to determine if they have been published or made available in a full report.</i></p> <p>Other resources of evidence:</p> <ul style="list-style-type: none"> <li>• Reference lists of included studies</li> <li>• Registered stakeholders</li> <li>• Trial authors and drug companies</li> <li>• Trial registries (<a href="http://www.controlled-trials.com/">http://www.controlled-trials.com/</a> ; <a href="https://www.clinicaltrialsregister.eu">https://www.clinicaltrialsregister.eu</a>)</li> <li>• PROSPERO</li> <li>• Non-English-language papers (with English abstracts) will be assessed for eligibility and potentially eligible studies will be checked to determine if they have been published in an English-language journal. Studies that have not been published in an English-language journal will not be included in the review.</li> </ul> <p><i>Note. Unpublished data will only be included where a full trial report is available with sufficient detail to properly assess the risk of bias. Authors of unpublished evidence will be asked for permission to use such data, and will be informed that summary data from the study and the study's characteristics will be published in the full guideline.</i></p>
4.	Condition or domain being studied	<p>Challenging behaviour and learning disabilities.</p> <p>Definitions: Challenging behaviour:</p>

Item No.	Item	Details
		<p>'Culturally abnormal behaviour(s) of such an intensity, frequency or duration that the physical safety of the person or others is likely to be placed in serious jeopardy, or behaviour which is likely to seriously limit use of, or result in the person being denied access to, ordinary community facilities'<sup>c</sup>.</p> <p>Learning disabilities: Heterogeneous conditions, but are defined by 3 core criteria: lower intellectual ability (usually defined as an IQ of less than 70), significant impairment of social or adaptive functioning and onset in childhood. This corresponds to 'mental retardation' as described in the major taxonomies DSM-IV and ICD-10.</p>
5.	Participants/population	<p>Children, young people and adults with a mild, moderate, severe or profound learning disability and their family carer and paid carers.</p> <p>Carers of people (children, young people and adults) with a learning disability and behaviour that challenges. The term 'carers' encompasses both family carers and paid carers.</p> <p>Definitions:</p> <ul style="list-style-type: none"> <li>• Family carer: <ul style="list-style-type: none"> <li>○ Has personal experience of caring for 1 or more persons with challenging behaviour and learning disabilities (CBLD) who is a family member;</li> <li>○ Has personal contact with a family member who has CBLD, even though that individual may not reside in the family home;</li> <li>○ Is not paid to have a personal, continuous relationship with a person with CBLD.</li> <li>○ Not all family carers may be related by blood, but choose to support a person with a learning disability in the way described above<sup>d</sup>.</li> </ul> </li> <li>• Paid carer: <ul style="list-style-type: none"> <li>○ Is paid to care for 1 or more persons with CBLD.</li> </ul> </li> </ul> <p>Exclude coexisting conditions (unless these affect interventions, management or support for people with a learning disability and behaviour that challenges).</p>
6.	Intervention(s), exposure(s)	RQ2.1: Assessment of the behaviour that challenges

<sup>c</sup> Emerson E. Challenging Behaviour: Analysis and Intervention in People with Learning Disabilities. 2nd edition. Cambridge: Cambridge University Press; 2001.

<sup>d</sup> Adapted from: Ward, C. Family Matters: Counting Families In. London: Department of Health; 2001.

Item No.	Item	Details
		<p>RQ2.2: Methods and tools for assessment (including assessment of sensory deficits, sensory processing disorders, physical health status, communication needs, emotional needs, individual, environmental risk factors and mental health needs)</p> <p>Assessment of environmental factors (including the physical environment, the social environment, parent, carers and staff attitudes, skills and staff competence)</p> <p>RQ2.3: Methods used to assess and monitor family carers and paid carers capacity to support the person with a learning disability and behaviour that challenges</p>
7.	Comparator(s)/control	N/A
8.	Types of study to be included initially	<p>RQ2.1: N/A; GDG consensus-based</p> <p>RQ2.2: Any</p> <p>RQ2.3: Any</p> <p>Excluded studies that did not use instruments in English, to ensure greatest applicability to the UK.</p>
9.	Context	Care and shared care provided or commissioned by health and social care, in whatever care setting the person resides.
10.	Primary/Critical outcomes	<p>RQ2.1: Clinical utility (including key components of, and the most effective structure for, an assessment of the behaviour that challenges across a range of settings)</p> <p>RQ2.2: Clinical utility (including sensitivity and specificity, utility and reliability)</p> <p>RQ2.3: Clinical utility (including sensitivity and specificity, utility and reliability)</p> <p>Definitions:</p> <ul style="list-style-type: none"> <li>• Clinical utility: the instrument should be feasible and implementable in a routine clinical care, especially primary care. The instrument should contribute to the identification of further assessment needs and inform decisions about referral to other services.</li> <li>• Psychometric data: The instrument should have established reliability and validity.</li> </ul>

Item No.	Item	Details
		<ul style="list-style-type: none"> <li>• Psychometric properties of instruments that meet inclusion criteria will be evaluated according to the following criteria:</li> <li>• Reliability</li> <li>• Inter-rater reliability – correlation between 2 raters (<math>r \geq 0.70</math>) = relatively reliable.</li> <li>• Test-retest reliability – stability of the instrument as shown by the correlation between test scores in the same group of participants across 2 different times (<math>r \geq 0.70</math>) = relatively reliable.</li> <li>• Internal consistency – the extent to which items measure a single construct (<math>r \geq 0.70</math> or <math>\alpha \geq 0.50</math>; <math>k \geq 0.40</math>) = relatively reliable.</li> <li>• Validity</li> <li>• Criterion validity – minimum <math>r = 0.50</math> (or some suggest 0.30 to 0.40 is more reasonable).</li> <li>• Criterion validity refers to the degree to which there is a relationship between the instrument and some other established standard of the measure of interest. There are 2 subtypes of criterion validity: (1) predictive validity (extent to which instrument scores are correlated with performance on some future criterion) and (2) concurrent validity (extent to which instrument scores are correlated with performance on a related criterion at the same time point).</li> <li>• Construct validity <math>r \geq 0.50</math> or discrimination index = 0.3 to 0.7. Construct validity refers to the degree to which the instrument measures the construct. Construct validity includes 2 subtypes: (1) discriminant validity (degree to which the instrument differentiates between constructs that are different, such as cases and controls) and (2) convergent validity (correlation between constructs that are similar).</li> </ul>
11.	Secondary/Important, but not critical outcomes	N/A
12.	Data extraction (selection and coding)	Citations from each search will be downloaded into EndNote and duplicates removed. Records will then be screened against the eligibility criteria of the review. The unfiltered search results will be saved and retained for future potential re-analysis. All primary-level studies included after the first scan of citations will be acquired in full and re-evaluated for eligibility at the time they are being entered into a study database (standardised template created in Microsoft Excel). Eligibility will be confirmed by at least 1 member of the GDG. The GDG are experts in the topic and/or research methodology. Two researchers will extract data into the study database, comparing a sample of each other's work for reliability. Discrepancies or difficulties with coding will be resolved through discussion with members of the GDG.
13.	Risk of bias (quality assessment)	The quality of individual studies will be assessed using the appropriate NICE quality assessment checklist.
14.	Strategy for data synthesis	<p>RQ2.1: The GDG will use a consensus-based approach to identify the key components of an effective assessment.</p> <p>RQ2.2-2.3: We will conduct pooled diagnostic accuracy meta-analyses on the sensitivity and specificity of methods and tools for assessment of people with challenging behaviour and a learning disability (dependent on available data).</p>



Item No.	Item	Details
		In the absence of adequate data, a narrative review of assessment methods and tools will be conducted and guided by a pre-defined list of consensus-based criteria (for example, the clinical utility of the tool and psychometric data evaluating its reliability and validity).
15.	Analysis of subgroups or subsets (including sensitivity analyses)	<p>Subgroups include:</p> <ul style="list-style-type: none"> <li>• Population: Children and young people; adults</li> <li>• Degree of learning disability: mild (an IQ of 50–69), moderate (an IQ of 35–49), severe (an IQ of 20–34) and profound (an IQ of less than 20).</li> </ul> <p>Form of challenging behaviour:</p> <ul style="list-style-type: none"> <li>• Self-injurious behaviour (includes head-banging, scratching, pulling, eye poking, picking, grinding teeth, eating non-foodstuffs)</li> <li>• Aggressive behaviour toward others (includes biting and scratching, hitting, pinching, grabbing, hair pulling, throwing objects, verbal abuse, screaming, spitting).</li> <li>• Stereotyped behaviour (including repetitive movements, rocking, repetitive speech and repetitive manipulation of objects).</li> <li>• Non-person directed behaviour (includes damage to property, hyperactivity, stealing, inappropriate sexualised behaviour, destruction of clothing, incontinence, lack of awareness of danger, withdrawal).</li> </ul>

### F.3.3 Topic: Prevention Interventions

Item No.	Item	Details
1.	Review question(s)	<p>RQ3.1: In people with a learning disability, what are the benefits and potential harms of interventions (including early intervention) aimed at preventing the development of behaviour that challenges?</p> <p>RQ3.2: In people with a learning disability, and their carers, what are the benefits and potential harms of interventions aimed at reducing health risks and increasing understanding of physical illness or mental health problems in relation to the prevention or management of the behaviour that challenges?</p>
2.	Sub-question(s)	RQ#:
3.	Searches	<p>RQ3.1,3.2:</p> <p>RCTs:</p> <p>Major bibliographic databases:</p>

Item No.	Item	Details
		<p>CENTRAL (inception to October 2014), CINAHL (inception to October 2014), Embase (inception to October 2014), MEDLINE/PreMEDLINE (inception to October 2014), PsycINFO (inception to October 2014)</p> <p>Topic databases:            AEI (inception to October 2014), ASSIA (inception to October 2014), BEI (inception to October 2014), ERIC (inception to October 2014), IBSS (inception to October 2014), SSCI (inception to October 2014), Sociological Abstracts (inception to October 2014), Social Services Abstracts (inception to October 2014)</p> <p>Systematic reviews of RCTs:            Major bibliographic databases            CDSR (1999 to October 2014), DARE (1999 to October 2014), CINAHL (1999 to October 2014), Embase (1999 to October 2014), MEDLINE/PreMEDLINE (1999 to October 2014), PsycINFO (1999 to October 2014)</p> <p>Topic databases:            AEI (1999 to October 2014), ASSIA (1999 to October 2014), BEI (1999 to October 2014), ERIC (1999 to October 2014), IBSS (1999 to October 2014), SSCI (1999 to October 2014), Sociological Abstracts (1999 to October 2014), Social Services Abstracts (1999 to October 2014)</p> <p><i>Note. Conference abstracts will be assessed for eligibility and potentially eligible studies will be checked to determine if they have been published or made available in a full report.</i></p> <p>Other resources of evidence:</p> <ul style="list-style-type: none"> <li>• Reference lists of included studies</li> <li>• Registered stakeholders</li> <li>• Trial authors and drug companies</li> <li>• Trial registries (<a href="http://www.controlled-trials.com/">http://www.controlled-trials.com/</a> ; <a href="https://www.clinicaltrialsregister.eu">https://www.clinicaltrialsregister.eu</a>)</li> <li>• PROSPERO</li> <li>• Non-English-language papers (with English abstracts) will be assessed for eligibility and potentially eligible studies will be checked to determine if they have been published in an English-language journal. Studies that have not been published in an English-language journal will not be included in the review.</li> </ul>

Item No.	Item	Details
		<i>Note. Unpublished data will only be included where a full trial report is available with sufficient detail to properly assess the risk of bias. Authors of unpublished evidence will be asked for permission to use such data, and will be informed that summary data from the study and the study's characteristics will be published in the full guideline.</i>
4.	Condition or domain being studied	<p>Challenging behaviour and learning disabilities</p> <p>Definitions:</p> <ul style="list-style-type: none"> <li>• Challenging behaviour: <ul style="list-style-type: none"> <li>○ 'Culturally abnormal behaviour(s) of such an intensity, frequency or duration that the physical safety of the person or others is likely to be placed in serious jeopardy, or behaviour which is likely to seriously limit use of, or result in the person being denied access to, ordinary community facilities'<sup>e</sup>.</li> </ul> </li> <li>• Learning disabilities: <ul style="list-style-type: none"> <li>○ Heterogeneous conditions, but are defined by 3 core criteria: lower intellectual ability (usually defined as an IQ of less than 70), significant impairment of social or adaptive functioning and onset in childhood. This corresponds to 'mental retardation' as described in the major taxonomies DSM-IV and ICD-10.</li> </ul> </li> </ul>
5.	Participants/population	<p>Children, young people and adults with a mild, moderate, severe or profound learning disability.</p> <p>Exclude coexisting conditions (unless these affect interventions, management or support for people with a learning disability and behaviour that challenges).</p> <p>If some, but not all, of a study's participants are eligible for our review, we will ask the study authors for disaggregated data. If we are unable to obtain the appropriate disaggregated data, then we will include a study only if: i) the majority of the study participants are eligible or participants are eligible on average (for example, the average IQ &lt; 70) and; ii) the GDG feel that the study's overall quality and directness is applicable to the review question.</p>
6.	Intervention(s), exposure(s)	<p>Categorisation of intervention based on participants risk:</p> <ul style="list-style-type: none"> <li>• Universal prevention intervention: Inclusion of people with a learning disability that have not been identified on the basis of increased risk.</li> <li>• Selective prevention intervention: Inclusion of people with a learning disability was done on the basis of risk factors (for example, biological, psychological, environmental or social) or a screening instrument based on risk factor research.</li> </ul>

<sup>e</sup> Emerson E. Challenging behaviour: analysis and Intervention in people with learning disabilities. Second edition. Cambridge: Cambridge University Press; 2001.

Item No.	Item	Details
		<ul style="list-style-type: none"> <li>Indicated prevention (IP) intervention: Inclusion of people with a learning disability was done on the basis of high risk with minimal but detectable signs or symptoms foreshadowing the development of behaviour that challenges, but who do not meet criteria for behaviour problems at the current time.</li> </ul> <p>RQ 3.1: Psychosocial; Pharmacological; Environmental; Complex interventions (for example, Combined psychological and pharmacological interventions)</p> <p>RQ3.2: Interventions aimed at reducing health risks and increasing an individual's and carers understanding of that persons physical illness or mental health problems, and thereby possibly reducing the contribution of untreated physical illness to the development and maintenance of behaviour that challenges.</p> <p>Excluded Interventions            Studies including participants exhibiting clinical significant behaviour that challenges.            Studies evaluating the process of interventions rather than outcomes (for example, uptake of programme)</p>
7.	Comparator(s)/control	Treatment as usual No treatment, waitlist control, attention control Any alternative prevention intervention
8.	Types of study to be included initially	RCTs and systematic reviews of RCTs.  Crossover randomised trials will be included only if data from the first phase is available.  In the first instance, only data from RCTs or systematic reviews of RCTs will be included. If the GDG consider the RCT evidence to be limited in terms of quality, directness or quantity, the range of included studies will be expanded to systematic reviews of non-randomised studies (that is, controlled before-after studies, interrupted time-series, small-n studies, observational studies). Such reviews will only be included if the review team and GDG agree that the systematic review of non-randomised studies is of adequate quality, completeness, and applicability to the NHS and to the scope of the guideline.
9.	Context	Care and shared care provided or commissioned by health and social care, in whatever care setting the person resides.
10.	Primary/Critical outcomes	RQ3.1 Behaviour that challenges (severity, frequency and duration) Adaptive functioning, including communication skills.

Item No.	Item	Details
		<p>Quality of life. Service user and carer satisfaction.</p> <p>RQ3.2 Behaviour that challenges (severity, frequency and duration) Adaptive functioning, including communication skills. Quality of life. Mental and psychological health outcomes (such as mood and anxiety). Physical health outcomes Service user and carer understanding of health risks Service user and carer satisfaction. Premature death.</p>
11.	Secondary/Important, but not critical outcomes	<p>RQ3.1 Mental and psychological health outcomes (such as mood and anxiety). Effects on carer stress and resilience. Adverse effects on other people with a learning disability. Rates of seclusion. Rates of manual restraint. Use of psychoactive medication. Premature death. Rates of placement breakdown. Use of inpatient placements (including out-of-area placements).</p> <p>RQ3.2 Effects on carer stress and resilience. Adverse effects on other people with a learning disability. Rates of seclusion. Rates of manual restraint. Use of psychoactive medication. Rates of placement breakdown. Use of inpatient placements (including out-of-area placements).</p>

Item No.	Item	Details
12.	Data extraction (selection and coding)	<p>Citations from each search will be downloaded into EndNote and duplicates removed. Records will then be screened against the eligibility criteria of the review. The unfiltered search results will be saved and retained for future potential re-analysis. All primary-level studies included after the first scan of citations will be acquired in full and re-evaluated for eligibility at the time they are being entered into a study database (standardised template created in Microsoft Excel). Eligibility will be confirmed by at least 1 member of the GDG. The GDG are experts in the topic and/or research methodology. Two researchers will extract data into the study database, comparing a sample of each other's work for reliability. Discrepancies or difficulties with coding will be resolved through discussion with members of the GDG.</p> <p>Data to be extracted:</p> <p>Study characteristics (study ID, year, intervention/comparison, context or setting, recruitment location, randomised N, diagnosis, target behaviour, IQ cut-off, run in/washout, inclusion/exclusion criteria, group assignment [number of groups, randomisation, N cluster], demographics [age, sex, race, IQ, and so on], funding, publication type, references, risk of bias [sequence generation, allocation concealment, blinding, missing outcome data, selective outcome reporting])</p> <p>Comparisons (N, N post-treatment, N follow-up, intervention, target group, dose type, dose, frequency, duration)</p> <p>Outcomes (outcome type, outcome name, data type, rater, weeks post-randomisation, time point – phase, outcome data [for example, mean, SD, N, events]).</p>
13.	Risk of bias (quality) assessment	<p>The quality of individual studies will be assessed using the appropriate NICE quality assessment checklist. The quality of evidence for each outcome will be assessed using the GRADE approach.</p>
14.	Strategy for data synthesis	<p>Where appropriate, meta-analysis using a random-effects model will be used to combine results from similar studies. Alternatively, a narrative synthesis will be used.</p> <p>If existing reviews are found, the review team with advice from the GDG will assess their quality, completeness, and applicability to the NHS and to the scope of the guideline. If the GDG agree that a systematic review appropriately addresses a review question, we will search for studies conducted or published since the review was conducted, and the GDG will assess if any additional studies could affect the conclusions of the previous review. If new studies could change the conclusions, we will update the review and conduct a new analysis. If new studies could not change the conclusions of an existing review, the GDG will use the existing review to inform their recommendations.</p>

Item No.	Item	Details
		<p>Repeated observations on participants: If studies reports results for several periods of follow-up (for example, 4 weeks, 12 weeks and 26 weeks post treatment) the longest follow-up from each study shall be utilised in analyses. If the GDG feel that periods of follow-up are sufficiently distanced by time, we shall consider defining several different outcomes, based on different periods of follow-up, and to perform separate analyses (for example, short-term, medium-term and long-term follow-up).</p> <p>Method of dealing with missing data Because imputation of missing data in order to perform a full intention to treat (ITT) analysis is controversial, only the results for available participants will be analysed in meta-analysis. However, for dichotomous outcomes a sensitivity analyses will be carried out whereby missing data will be imputed according to worst case scenario. Outcomes from the sensitivity analysis will only be presented if the ITT analysis differs significantly from the available case analysis.</p> <p>GRADE methods While considering all of the below, our decisions will be based a greater amount on those studies that carry the greatest weight within the outcome. If weight is distributed equally, all studies shall be considered equally. Risk of bias: mark down 1 risk of bias (ROB) if a single study demonstrates a crucial limitation for 1 criterion or some limitations for multiple, odds ratio (OR) if risk of bias across multiple studies is at moderate ROB; mark down 2 if there is a crucial limitation for 1 or more criteria within a study OR if risk of bias across multiple studies is at high ROB. Inconsistency: mark down 1 if <math>I^2 &gt; 40\%</math>; mark down 2 if <math>I^2 &gt; 75\%</math>. We shall also consider the variability in point estimates, overlap of CI and P-value (&lt;0.05) in our decision. Indirectness: review applicability of intervention, population and comparison. Consider down grading if &gt;33% of population is not relevant, if the intervention is not aimed primarily at reducing the targeted behaviour that challenges, or if the comparison may reduce our confidence in the effect. Imprecision: mark down 1 if optimal information size is not met with multiple studies<sup>f</sup>; mark down 2 if optimal information size is not met with a single study. Publication bias: Where possible, use funnel plots to determine the presence of publication bias. If this is not possible, and we have a strong suspicion that publication bias is present, mark down a maximum of 1.</p>
15.	Analysis of subgroups or subsets (including sensitivity analyses)	<p>Subgroups include:</p> <ul style="list-style-type: none"> <li>• Population: Children and young people; adults</li> <li>• Degree of learning disability: mild (an IQ of 50–69), moderate (an IQ of 35–49), severe (an IQ of 20–34) and profound (an IQ of less than 20).</li> </ul>

<sup>f</sup> Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology. 2011;64:383-94.

Item No.	Item	Details
		<ul style="list-style-type: none"> <li>• Form of challenging behaviour:</li> <li>• Self-injurious behaviour (includes head-banging, scratching, pulling, eye poking, picking, grinding teeth, eating non-foodstuffs)</li> <li>• Aggressive behaviour toward others (includes biting and scratching, hitting, pinching, grabbing, hair pulling, throwing objects, verbal abuse, screaming, spitting).</li> <li>• Stereotyped behaviour (including repetitive movements, rocking, repetitive speech and repetitive manipulation of objects).</li> <li>• Non-person directed behaviour (includes damage to property, hyperactivity, stealing, inappropriate sexualised behaviour, destruction of clothing, incontinence, lack of awareness of danger, withdrawal).</li> </ul> <p>Sensitivity analyses:</p> <ul style="list-style-type: none"> <li>• Exclude RCT studies with &lt;10 participants per arm.</li> </ul>

### F.3.4 Topic: Treatment interventions/management strategies

Item No.	Item	Details
1.	Review question(s)	<p>RQ4.1: In people with a learning disability and behaviour that challenges, what are the benefits and potential harms associated with environmental changes (including the physical and social environments) aimed at reducing and managing behaviour that challenges<sup>9</sup>?</p> <p>RQ4.2: In people with a learning disability and behaviour that challenges, what are the benefits and potential harms associated with psychosocial interventions (including a broad range of therapies, such as communication interventions, applied behaviour analysis, positive behaviour support and cognitive behavioural therapy) aimed at reducing and managing behaviour that challenges?</p> <p>RQ4.3: In people with a learning disability and behaviour that challenges, what are the benefits and potential harms associated with pharmacological interventions aimed at reducing and managing behaviour that challenges?</p> <p>RQ4.4: In people with a learning disability and behaviour that challenges, what are the benefits and potential harms of 'reactive strategies' (including physical restraint, mechanical restraint, confinement, and containment and seclusion) aimed at managing behaviour that challenges?</p>

<sup>9</sup> Including potentially offending behaviour.



Item No.	Item	Details
2.	Sub-question(s)	N/A
3.	Searches	<p>RQ4.1, 4.2, 4.3, 4.4</p> <p>RCT: Major bibliographic databases: CENTRAL (inception to October 2014), CINAHL (inception to October 2014), Embase (inception to October 2014), MEDLINE/PreMEDLINE (inception to October 2014), PsycINFO (inception to October 2014)</p> <p>Topic databases: AEI (inception to October 2014), ASSIA (inception to October 2014), BEI (inception to October 2014), ERIC (inception to October 2014), IBSS (inception to October 2014), SSCI (inception to October 2014), Sociological Abstracts (inception to October 2014), Social Services Abstracts (inception to October 2014)</p> <p>Systematic reviews of RCTs: Major bibliographic databases CDSR (1999 to October 2014), DARE (1999 to October 2014), CINAHL (1999 to October 2014), Embase (1999 to October 2014), MEDLINE/PreMEDLINE (1999 to October 2014), PsycINFO (1999 to October 2014)</p> <p>Topic databases: AEI (1999 to October 2014), ASSIA (1999 to October 2014), BEI (1999 to October 2014), ERIC (1999 to October 2014), IBSS (1999 to October 2014), SSCI (1999 to October 2014), Sociological Abstracts (1999 to October 2014), Social Services Abstracts (1999 to October 2014)</p> <p><i>Note. Conference abstracts will be assessed for eligibility and potentially eligible studies will be checked to determine if they have been published or made available in a full report.</i></p> <p>Other resources of evidence:</p> <ul style="list-style-type: none"> <li>• Reference lists of included studies</li> <li>• Registered stakeholders</li> <li>• Trial authors and drug companies</li> <li>• Trial registries (<a href="http://www.controlled-trials.com/">http://www.controlled-trials.com/</a>; <a href="https://www.clinicaltrialsregister.eu">https://www.clinicaltrialsregister.eu</a>)</li> </ul>

Item No.	Item	Details
		<ul style="list-style-type: none"> <li>• PROSPERO</li> <li>• Non-English-language papers (with English abstracts) will be assessed for eligibility and potentially eligible studies will be checked to determine if they have been published in an English-language journal. Studies that have not been published in an English-language journal will not be included in the review.</li> </ul> <p><i>Note. Unpublished data will only be included where a full trial report is available with sufficient detail to properly assess the risk of bias. Authors of unpublished evidence will be asked for permission to use such data, and will be informed that summary data from the study and the study's characteristics will be published in the full guideline.</i></p>
4.	Condition or domain being studied	<p>Challenging behaviour and learning disabilities</p> <p>Definitions:</p> <ul style="list-style-type: none"> <li>• Challenging behaviour: <ul style="list-style-type: none"> <li>○ 'Culturally abnormal behaviour(s) of such an intensity, frequency or duration that the physical safety of the person or others is likely to be placed in serious jeopardy, or behaviour which is likely to seriously limit use of, or result in the person being denied access to, ordinary community facilities'<sup>h</sup>.</li> </ul> </li> <li>• Learning disabilities: <ul style="list-style-type: none"> <li>○ Heterogeneous conditions, but are defined by 3 core criteria: lower intellectual ability (usually defined as an IQ of less than 70), significant impairment of social or adaptive functioning and onset in childhood. This corresponds to 'mental retardation' as described in the major taxonomies DSM-IV and ICD-10.</li> </ul> </li> </ul>
5.	Participants/population	<p>Children, young people and adults with a mild, moderate, severe or profound learning disability and behaviour that challenges.</p> <p>Exclude coexisting conditions (unless these affect interventions, management or support for people with a learning disability and behaviour that challenges).</p> <p>If some, but not all, of a study's participants are eligible for our review, we will ask the study authors for disaggregated data. If we are unable to obtain the appropriate disaggregated data, then we will include a study only if: i) the majority of the study participants are eligible or participants are eligible on average (for example, the average IQ &lt; 70) and; ii) the GDG feel that the study's overall quality and directness is applicable to the review question.</p>

<sup>h</sup> Emerson E. Challenging behaviour: analysis and Intervention in people with learning disabilities. 2nd edition. Cambridge: Cambridge University Press; 2001.

Item No.	Item	Details
6.	Intervention(s), exposure(s)	<p>Included interventions</p> <p>RQ4.1: Environmental changes (including the physical and social environments)</p> <p>RQ4.2: Psychosocial interventions (including a broad range of therapies, such as communication interventions, applied behaviour analysis, positive behaviour support and cognitive behavioural therapy)</p> <p>RQ4.3: Pharmacological interventions</p> <p>RQ4.4: 'Reactive strategies' (including physical restraint, mechanical restraint, confinement, and containment and seclusion)</p> <p>Excluded interventions: Interventions that are not targeted at reducing/managing behaviour that challenges. Studies evaluating the process of interventions rather than outcomes (for example, uptake of programme)</p>
7.	Comparator(s)/control	<p>Treatment as usual</p> <p>No treatment, placebo, waitlist control, attention control</p> <p>Any alternative management strategy</p>
8.	Types of study to be included initially	<p>RCTs and systematic reviews of RCTs.</p> <p>Crossover randomised trials will be included only if data from the first phase is available.</p> <p>In the first instance, only data from RCTs or systematic reviews of RCTs will be included. If the GDG consider the RCT evidence to be limited in terms of quality, directness or quantity, the range of included studies will be expanded to systematic reviews of non-randomised studies (that is, controlled before-after studies, interrupted time-series, small-n studies, observational studies). Such reviews will only be included if the review team and GDG agree that the systematic review of non-randomised studies is of adequate quality, completeness, and applicability to the NHS and to the scope of the guideline.</p>
9.	Context	Care and shared care provided or commissioned by health and social care, in whatever care setting the person resides.
10.	Primary/Critical outcomes	RQ4.1-4.3:

Item No.	Item	Details
		<p>Targeted behaviour that challenges<sup>i</sup> (severity, frequency and duration)                      Adaptive functioning, including communication skills                      Quality of life                      Service user and carer satisfaction.                      Adverse events (for 4.3 only including sedation/somnolence/drowsiness, weight outcomes, prolactin level outcomes, seizures, study discontinuation due to adverse events, study discontinuation due to other reasons).</p> <p>RQ4.4:                      Targeted behaviour that challenges (severity, frequency and duration)                      Rates of manual restraint                      Rates of seclusion                      Quality of life                      Service user and carer satisfaction.</p>
11.	Secondary/Important, but not critical outcomes	<p>RQ4.1-4.3:                      Mental and psychological health outcomes (such as mood and anxiety)                      Effects on carer stress and resilience                      Adverse effects on other people with a learning disability                      Rates of seclusion                      Rates of manual restraint                      Use of psychoactive medication                      Premature death                      Rates of placement breakdown                      Use of inpatient placements (including out-of-area placements).</p> <p>RQ4.4:                      Mental and psychological health outcomes (such as mood and anxiety)                      Adaptive functioning, including communication skills                      Effects on carer stress and resilience                      Adverse effects on other people with a learning disability</p>

<sup>i</sup> Including offending behaviour.

Item No.	Item	Details
		<p>Use of psychoactive medication</p> <p>Premature death</p> <p>Rates of placement breakdown</p> <p>Use of inpatient placements (including out-of-area placements).</p>
12.	Data extraction (selection and coding)	<p>Citations from each search will be downloaded into EndNote and duplicates removed. Records will then be screened against the eligibility criteria of the review. The unfiltered search results will be saved and retained for future potential re-analysis. All primary-level studies included after the first scan of citations will be acquired in full and re-evaluated for eligibility at the time they are being entered into a study database (standardised template created in Microsoft Excel). Eligibility will be confirmed by at least 1 member of the GDG. The GDG are experts in the topic and/or research methodology. Two researchers will extract data into the study database, comparing a sample of each other's work for reliability. Discrepancies or difficulties with coding will be resolved through discussion with members of the GDG.</p> <p>Data to be extracted:</p> <p>Study characteristics (study ID, year, intervention/comparison, context or setting, recruitment location, randomised N, diagnosis, target behaviour, IQ cut-off, run in/washout, inclusion/exclusion criteria, group assignment [number of groups, randomisation, N cluster], demographics [age, sex, race, IQ, and so on], funding, publication type, references, risk of bias [sequence generation, allocation concealment, blinding, missing outcome data, selective outcome reporting])</p> <p>Comparisons (N, N post-treatment, N follow-up, intervention, target group, dose type, dose, frequency, duration)</p> <p>Outcomes (outcome type, outcome name, data type, rater, weeks post-randomisation, time point – phase, outcome data [for example, mean, SD, N, events]).</p>
13.	Risk of bias (quality) assessment	<p>The quality of individual studies will be assessed using the appropriate NICE quality assessment checklist. The quality of evidence for each outcome will be assessed using the GRADE approach.</p>
14.	Strategy for data synthesis	<p>Where appropriate, meta-analysis using a random-effects model will be used to combine results from similar studies. Alternatively, a narrative synthesis will be used.</p> <p>If existing reviews are found, the review team with advice from the GDG will assess their quality, completeness, and applicability to the NHS and to the scope of the guideline. If the GDG agree that a systematic review appropriately addresses a review question, we will search for studies conducted or published since the review was conducted, and the GDG will assess if any additional studies could affect the conclusions of the previous review. If new studies could change the conclusions, we will update the review and conduct a new analysis. If new studies could not change the conclusions of an existing review, the GDG will use the existing review to inform their recommendations.</p>

Item No.	Item	Details
		<p>Repeated observations on participants: If studies reports results for several periods of follow-up (for example, 4 weeks, 12 weeks and 26 weeks post treatment) the longest follow-up from each study shall be utilised in analyses. If the GDG feel that periods of follow-up are sufficiently distanced by time, we shall consider defining several different outcomes, based on different periods of follow-up, and to perform separate analyses (for example, short-term, medium-term and long-term follow-up).</p> <p>Method of dealing with missing data Because imputation of missing data in order to perform a full ITT analysis is controversial, only the results for available participants will be analysed in meta-analysis. However, for dichotomous outcomes a sensitivity analyses will be carried out whereby missing data will be imputed according to worst case scenario. Outcomes from the sensitivity analysis will only be presented if the ITT analysis differs significantly from the available case analysis.</p> <p>GRADE methods: While considering all of the below, our decisions will mainly be based on those studies that carry the greatest weight within the outcome. If weight is distributed equally, all studies shall be considered equally. Risk of bias: mark down 1 ROB if a single study demonstrates a crucial limitation for 1 criterion or some limitations for multiple, OR if risk of bias across multiple studies is at moderate ROB; mark down 2 if there is a crucial limitation for 1 or more criteria within a study OR if risk of bias across multiple studies is at high ROB. Inconsistency: mark down 1 if <math>I^2 &gt; 40\%</math>; mark down 2 if <math>I^2 &gt; 75\%</math>. We shall also consider the variability in point estimates, overlap of CI and P-value (<math>&lt;0.05</math>) in our decision. Indirectness: review applicability of intervention, population and comparison. Consider down grading if <math>&gt;33\%</math> of population is not relevant, if the intervention is not aimed primarily at reducing the targeted behaviour that challenges, or if the comparison may reduce our confidence in the effect. Imprecision: mark down 1 if optimal information size is not met with multiple studies (Guyatt, 2011); mark down 2 if optimal information size is not met with a single study. Publication bias: Where possible, use funnel plots to determine the presence of publication bias. If this is not possible, and we have a strong suspicion that publication bias is present, mark down a maximum of 1.</p>
15.	Analysis of subgroups or subsets (including sensitivity analyses)	<p>Subgroups include: Population: Children and young people; adults Degree of learning disability: mild (an IQ of 50–69), moderate (an IQ of 35–49), severe (an IQ of 20–34) and profound (an IQ of less than 20).</p> <p>Form of challenging behaviour:</p>

Item No.	Item	Details
		<p>Self-injurious behaviour (includes head-banging, scratching, pulling, eye poking, picking, grinding teeth, eating non-foodstuffs)</p> <p>Aggressive behaviour toward others (includes biting and scratching, hitting, pinching, grabbing, hair pulling, throwing objects, verbal abuse, screaming, spitting)</p> <p>Stereotyped behaviour (including repetitive movements, rocking, repetitive speech and repetitive manipulation of objects).</p> <p>Non-person directed behaviour (includes damage to property, hyperactivity, stealing, inappropriate sexualised behaviour, destruction of clothing, incontinence, lack of awareness of danger, withdrawal).</p> <p>Sensitivity analyses: Exclude RCT studies with &lt;10 participants per arm.</p>

### F.3.5 Topic: Interventions for family and carers

Item No.	Item	Details
1.	Review question(s)	<p>RQ5.1: In family and carers of people with a learning disability and behaviour that challenges, what are the benefits and potential harms of interventions aimed at improving their health and well-being?</p> <p>RQ5.2: What are the benefits and potential harms of strategies aimed at engaging the family and carers of people with a learning disability and challenging behaviour as a resource in the design, implementation and monitoring of interventions for the person with a learning disability and challenging behaviour?</p>
2.	Sub-question(s)	RQ#:
3.	Searches	<p>RQ5.1, 5.2</p> <p>RCT: Major bibliographic databases: CENTRAL (inception to October 2014), CINAHL (inception to October 2014), Embase (inception to October 2014), MEDLINE/PreMEDLINE (inception to October 2014), PsycINFO (inception to October 2014)</p> <p>Topic databases: AEI (inception to October 2014), ASSIA (inception to October 2014), BEI (inception to October 2014), ERIC (inception to October 2014), IBSS (inception to October 2014), SSCI (inception to October 2014), Sociological Abstracts (inception to October 2014), Social Services Abstracts (inception to October 2014)</p>

Item No.	Item	Details
		<p>Systematic reviews of RCTs: Major bibliographic databases CDSR (1999 to October 2014), DARE (1999 to October 2014), CINAHL (1999 to October 2014), Embase (1999 to October 2014), MEDLINE/PreMEDLINE (1999 to October 2014), PsycINFO (1999 to October 2014)</p> <p>Topic databases: AEI (1999 to October 2014), ASSIA (1999 to October 2014), BEI (1999 to October 2014), ERIC (1999 to October 2014), IBSS (1999 to October 2014), SSCI (1999 to October 2014), Sociological Abstracts (1999 to October 2014), Social Services Abstracts (1999 to October 2014)</p> <p><i>Note. Conference abstracts will be assessed for eligibility and potentially eligible studies will be checked to determine if they have been published or made available in a full report.</i></p> <p>Other resources of evidence:</p> <ul style="list-style-type: none"> <li>• Reference lists of included studies</li> <li>• Registered stakeholders</li> <li>• Trial authors and drug companies</li> <li>• Trial registries (<a href="http://www.controlled-trials.com/">http://www.controlled-trials.com/</a>; <a href="https://www.clinicaltrialsregister.eu">https://www.clinicaltrialsregister.eu</a>)</li> <li>• PROSPERO</li> <li>• Non-English-language papers (with English abstracts) will be assessed for eligibility and potentially eligible studies will be checked to determine if they have been published in an English-language journal. Studies that have not been published in an English-language journal will not be included in the review.</li> </ul> <p><i>Note. Unpublished data will only be included where a full trial report is available with sufficient detail to properly assess the risk of bias. Authors of unpublished evidence will be asked for permission to use such data, and will be informed that summary data from the study and the study's characteristics will be published in the full guideline.</i></p>
4.	Condition or domain being studied	<p>Challenging behaviour and learning disabilities.</p> <p>Definitions:</p> <ul style="list-style-type: none"> <li>• Challenging behaviour:</li> </ul>



Item No.	Item	Details
		<ul style="list-style-type: none"> <li>○ ‘Culturally abnormal behaviour(s) of such an intensity, frequency or duration that the physical safety of the person or others is likely to be placed in serious jeopardy, or behaviour which is likely to seriously limit use of, or result in the person being denied access to, ordinary community facilities’<sup>i</sup>.</li> <li>● Learning disabilities: <ul style="list-style-type: none"> <li>○ Heterogeneous conditions, but are defined by 3 core criteria: lower intellectual ability (usually defined as an IQ of less than 70), significant impairment of social or adaptive functioning and onset in childhood. This corresponds to ‘mental retardation’ as described in the major taxonomies DSM-IV and ICD-10.</li> </ul> </li> </ul>
5.	Participants/population	<p>Family and carers of children, young people or adults with a mild, moderate, severe or profound learning disability and behaviour that challenges. The term ‘carers’ encompasses both family carers and paid carers.</p> <p>Definitions:</p> <ul style="list-style-type: none"> <li>● Family carer: <ul style="list-style-type: none"> <li>○ Has personal experience of caring for 1 or more persons with CBLD who is a family member;</li> <li>○ Has personal contact with a family member who has CBLD, even though that individual may not reside in the family home;</li> <li>○ Is not paid to have a personal, continuous relationship with a person with CBLD.</li> <li>○ Not all family carers may be related by blood, but choose to support a person with a learning disability in the way described above<sup>k</sup>. Family matters: counting families in. London: Department of Health.]’</li> </ul> </li> <li>● Paid carer: <ul style="list-style-type: none"> <li>○ Is paid to care for 1 or more persons with CBLD.</li> </ul> </li> </ul> <p>Exclude family and carers of people with coexisting conditions (unless these affect interventions, management or support for family and carers of people with a learning disability and behaviour that challenges).</p>
6.	Intervention(s), exposure(s)	<p>Included interventions All interventions targeted at improving health and well-being of family and carers</p> <p>Excluded Interventions</p>

<sup>i</sup> Emerson E. Challenging behaviour: analysis and Intervention in people with learning disabilities. 2nd edition. Cambridge: Cambridge University Press; 2001.

<sup>k</sup> Adapted from: Ward, C. Family Matters: Counting Families In. London: Department of Health; 2001.

Item No.	Item	Details
		Interventions targeted at improving health and well-being of children, young people or adults with a learning disability and behaviour that challenges. Studies evaluating the process of interventions rather than outcomes (for example, uptake of programme)
7.	Comparator(s)/control	Treatment as usual No treatment, waitlist control, attention control Any alternative management strategy
8.	Types of study to be included initially	RCTs and systematic reviews of RCTs.  Crossover randomised trials will be included only if data from the first phase is available.  In the first instance, only data from RCTs or systematic reviews of RCTs will be included. If the GDG consider the RCT evidence to be limited in terms of quality, directness or quantity, the range of included studies will be expanded to systematic reviews of non-randomised studies (that is, controlled before-after studies, interrupted time-series, small-n studies, observational studies). Such reviews will only be included if the review team and GDG agree that the systematic review of non-randomised studies is of adequate quality, completeness, and applicability to the NHS and to the scope of the guideline.  If no evidence is identified, formal methods of consensus shall be employed to ensure maximum transparency where possible.
9.	Context	Care and shared care provided or commissioned by health and social care, in whatever care setting the person resides.
10.	Primary/Critical outcomes	RQ5.1 Family and carer quality of life. Family and carer mental and psychological health outcomes (such as mood and anxiety). Family and carer stress and resilience. Family and carer satisfaction.  RQ5.2 Severity, frequency and duration of the targeted behaviour that challenges. Quality of life. Family and carer stress and resilience. Use of inpatient placements (including out-of-area placements).

Item No.	Item	Details
11.	Secondary/Important, but not critical outcomes	<p>Service user and carer satisfaction.</p> <p>RQ5.1  Severity, frequency and duration of the targeted behaviour that challenges.  Adaptive functioning, including communication skills.  Mental and psychological health outcomes (such as mood and anxiety).  Quality of life  Adverse effects on other people with a learning disability.  Rates of seclusion.  Rates of manual restraint.  Use of psychoactive medication.  Premature death.  Rates of placement breakdown.  Use of inpatient placements (including out-of-area placements).</p> <p>RQ5.2  Adaptive functioning, including communication skills.  Family and carer mental and psychological health outcomes (such as mood and anxiety).  Mental and psychological health outcomes (such as mood and anxiety).  Quality of life  Adverse effects on other people with a learning disability.  Rates of seclusion.  Rates of manual restraint.  Use of psychoactive medication.  Premature death.  Rates of placement breakdown.</p>
12.	Data extraction (selection and coding)	<p>Citations from each search will be downloaded into EndNote and duplicates removed. Records will then be screened against the eligibility criteria of the review. The unfiltered search results will be saved and retained for future potential re-analysis. All primary-level studies included after the first scan of citations will be acquired in full and re-evaluated for eligibility at the time they are being entered into a study database (standardised template created in Microsoft Excel). Eligibility will be confirmed by at least 1 member of the GDG. The GDG are experts in the topic and/or research</p>

Item No.	Item	Details
		<p>methodology. Two researchers will extract data into the study database, comparing a sample of each other's work for reliability. Discrepancies or difficulties with coding will be resolved through discussion with members of the GDG.</p> <p>Data to be extracted:</p> <p>Study characteristics (study ID, year, intervention/comparison, context or setting, recruitment location , randomised N, diagnosis, target behaviour, IQ cut-off, run in/washout, inclusion/exclusion criteria, group assignment [number of groups, randomisation, N cluster], demographics [age, sex, race, IQ, and so on], funding, publication type, references, risk of bias [sequence generation, allocation concealment, blinding, missing outcome data, selective outcome reporting])</p> <p>Comparisons (N, N post-treatment, N follow-up, intervention, target group, dose type, dose, frequency, duration)</p> <p>Outcomes (outcome type, outcome name, data type, rater, weeks post-randomisation, time point – phase, outcome data [for example, mean, SD, N, events]).</p>
13.	Risk of bias (quality) assessment	<p>The quality of individual studies will be assessed using the appropriate NICE quality assessment checklist. The quality of evidence for each outcome will be assessed using the GRADE approach.</p>
14.	Strategy for data synthesis	<p>Where appropriate, meta-analysis using a random-effects model will be used to combine results from similar studies. Alternatively, a narrative synthesis will be used.</p> <p>If existing reviews are found, the review team with advice from the GDG will assess their quality, completeness, and applicability to the NHS and to the scope of the guideline. If the GDG agree that a systematic review appropriately addresses a review question, we will search for studies conducted or published since the review was conducted, and the GDG will assess if any additional studies could affect the conclusions of the previous review. If new studies could change the conclusions, we will update the review and conduct a new analysis. If new studies could not change the conclusions of an existing review, the GDG will use the existing review to inform their recommendations.</p> <p>Repeated observations on participants:</p> <p>If studies reports results for several periods of follow-up (for example, 4 weeks, 12 weeks and 26 weeks post treatment) the longest follow-up from each study shall be utilised in analyses. If the GDG feel that periods of follow-up are sufficiently distanced by time, we shall consider defining several different outcomes, based on different periods of follow-up, and to perform separate analyses (for example, short-term, medium-term and long-term follow-up).</p> <p>Method of dealing with missing data</p>

Item No.	Item	Details
		<p>Because imputation of missing data in order to perform a full ITT analysis is controversial, only the results for available participants will be analysed in meta-analysis. However, for dichotomous outcomes a sensitivity analyses will be carried out whereby missing data will be imputed according to worst case scenario. Outcomes from the sensitivity analysis will only be presented if the ITT analysis differs significantly from the available case analysis.</p> <p>GRADE methods</p> <p>While considering all of the below, our decisions will be based a greater amount on those studies that carry the greatest weight within the outcome. If weight is distributed equally, all studies shall be considered equally.</p> <p>Risk of bias: mark down 1 ROB if a single study demonstrates a crucial limitation for 1 criterion or some limitations for multiple, OR if risk of bias across multiple studies is at moderate ROB; mark down 2 if there is a crucial limitation for 1 or more criteria within a study OR if risk of bias across multiple studies is at high ROB.</p> <p>Inconsistency: mark down 1 if <math>I^2 &gt; 40\%</math>; mark down 2 if <math>I^2 &gt; 75\%</math>. We shall also consider the variability in point estimates, overlap of CI and P-value (<math>&lt;0.05</math>) in our decision.</p> <p>Indirectness: review applicability of intervention, population and comparison. Consider down grading if <math>&gt;33\%</math> of population is not relevant, if the intervention is not aimed primarily at reducing the targeted behaviour that challenges, or if the comparison may reduce our confidence in the effect.</p> <p>Imprecision: mark down 1 if optimal information size is not met with multiple studies (Guyatt, 2011); mark down 2 if optimal information size is not met with a single study.</p> <p>Publication bias: Where possible, use funnel plots to determine the presence of publication bias. If this is not possible, and we have a strong suspicion that publication bias is present, mark down a maximum of 1.</p>
15.	Analysis of subgroups or subsets (including sensitivity analyses)	<p>Subgroups include: Population: Family carers, paid carers.</p> <p>Definitions:</p> <ul style="list-style-type: none"> <li>• Family carer: <ul style="list-style-type: none"> <li>○ Has personal experience of caring for 1 or more persons with CBLD who is a family member;</li> <li>○ Has personal contact with a family member who has CBLD, even though that individual may not reside in the family home;</li> <li>○ Is not paid to have a personal, continuous relationship with a person with CBLD.</li> <li>○ Not all family carers may be related by blood, but choose to support a person with a learning disability in the way described above<sup>1</sup>. Family matters: counting families in. London: Department of Health.]</li> </ul> </li> </ul>

<sup>1</sup> Adapted from: Ward, C. Family Matters: Counting Families In. London: Department of Health; 2001.

Item No.	Item	Details
		<ul style="list-style-type: none"> <li>• Paid carer: <ul style="list-style-type: none"> <li>○ Is paid to care for 1 or more persons with CBLD.</li> </ul> </li> </ul> <p>Sensitivity analyses: Exclude RCT studies with &lt;10 participants per arm</p>

### F.3.6 Topic: Training or education

Item No.	Item	Details
1.	Review question(s)	RQ6.1: What are the benefits and potential harms of training and education programmes to allow health and social care professionals and carers to provide good-quality services and carry out evidence based interventions designed to reduce or manage behaviour that challenges in people with a learning disability?
2.	Sub-question(s)	RQ#:
3.	Searches	<p>RCT:</p> <p>Major bibliographic databases: CENTRAL (inception to October 2014), CINAHL (inception to October 2014), Embase (inception to October 2014), MEDLINE/PreMEDLINE (inception to October 2014), PsycINFO (inception to October 2014)</p> <p>Topic databases: AEI (inception to October 2014), ASSIA (inception to October 2014), BEI (inception to October 2014), ERIC (inception to October 2014), IBSS (inception to October 2014), SSCI (inception to October 2014), Sociological Abstracts (inception to October 2014), Social Services Abstracts (inception to October 2014)</p> <p>Systematic reviews of RCTs: Major bibliographic databases CDSR (1999 to October 2014), DARE (1999 to October 2014), CINAHL (1999 to October 2014), Embase (1999 to October 2014), MEDLINE/PreMEDLINE (1999 to October 2014), PsycINFO (1999 to October 2014)</p> <p>Topic databases: AEI (1999 to October 2014), ASSIA (1999 to October 2014), BEI (1999 to October 2014), ERIC (1999 to October 2014), IBSS (1999 to October 2014), SSCI (1999 to October 2014), Sociological Abstracts (1999 to October 2014), Social Services Abstracts (1999 to October 2014)</p>

Item No.	Item	Details
		<p><i>Note. Conference abstracts will be assessed for eligibility and potentially eligible studies will be checked to determine if they have been published or made available in a full report.</i></p> <p>Other resources of evidence:</p> <ul style="list-style-type: none"> <li>• Reference lists of included studies</li> <li>• Registered stakeholders</li> <li>• Trial authors and drug companies</li> <li>• Trial registries (<a href="http://www.controlled-trials.com/">http://www.controlled-trials.com/</a>; <a href="https://www.clinicaltrialsregister.eu">https://www.clinicaltrialsregister.eu</a>)</li> <li>• PROSPERO</li> <li>• Non-English-language papers (with English abstracts) will be assessed for eligibility and potentially eligible studies will be checked to determine if they have been published in an English-language journal. Studies that have not been published in an English-language journal will not be included in the review.</li> </ul> <p><i>Note. Unpublished data will only be included where a full trial report is available with sufficient detail to properly assess the risk of bias. Authors of unpublished evidence will be asked for permission to use such data, and will be informed that summary data from the study and the study's characteristics will be published in the full guideline.</i></p>
4.	Condition or domain being studied	<p>Challenging behaviour and learning disabilities</p> <p>Definitions:</p> <ul style="list-style-type: none"> <li>• Challenging behaviour: <ul style="list-style-type: none"> <li>○ 'Culturally abnormal behaviour(s) of such an intensity, frequency or duration that the physical safety of the person or others is likely to be placed in serious jeopardy, or behaviour which is likely to seriously limit use of, or result in the person being denied access to, ordinary community facilities'<sup>m</sup>.</li> </ul> </li> <li>• Learning disabilities: <ul style="list-style-type: none"> <li>○ Heterogeneous conditions, but are defined by 3 core criteria: lower intellectual ability (usually defined as an IQ of less than 70), significant impairment of social or adaptive functioning and onset in childhood. This corresponds to 'mental retardation' as described in the major taxonomies DSM-IV and ICD-10.</li> </ul> </li> </ul>

<sup>m</sup> Emerson E. Challenging behaviour: analysis and Intervention in people with learning disabilities. 2nd edition. Cambridge: Cambridge University Press; 2001.

Item No.	Item	Details
5.	Participants/population	<p>Health and social care professionals, and carers of children, young people or adults with a mild, moderate, severe or profound learning disability and behaviour that challenges. The term 'carers' encompasses both family carers and paid carers.</p> <p>Definitions:</p> <ul style="list-style-type: none"> <li>• Family carer: <ul style="list-style-type: none"> <li>○ Has personal experience of caring for 1 or more persons with CBLD who is a family member;</li> <li>○ Has personal contact with a family member who has CBLD, even though that individual may not reside in the family home;</li> <li>○ Is not paid to have a personal, continuous relationship with a person with CBLD.</li> <li>○ Not all family carers may be related by blood, but choose to support a person with a learning disability in the way described above<sup>n</sup>. Family matters: counting families in. London: Department of Health.]]</li> </ul> </li> <li>• Paid carer: <ul style="list-style-type: none"> <li>○ Is paid to care for 1 or more persons with CBLD.</li> </ul> </li> </ul> <p>Exclude coexisting conditions (unless these affect interventions, management or support for people with a learning disability and behaviour that challenges).</p>
6.	Intervention(s), exposure(s)	<p>Included interventions Training and education programs to allow health and social care professionals and carers provide good-quality services and carry out evidence based interventions targeted at the reduction or management of behaviour that challenges.</p> <p>Excluded interventions Training or education programs not targeted at the reduction or management of behaviour that challenges.</p>
7.	Comparator(s)/control	<p>Treatment as usual No treatment, waitlist control, attention control Any alternative management strategy</p>
8.	Types of study to be included initially	<p>RCTs and systematic reviews of RCTs.</p> <p>Crossover randomised trials will be included only if data from the first phase is available.</p>

<sup>n</sup> Adapted from: Ward, C. Family Matters: Counting Families In. London: Department of Health; 2001.



Item No.	Item	Details
		In the first instance, only data from RCTs or systematic reviews of RCTs will be included. If the GDG consider the RCT evidence to be limited in terms of quality, directness or quantity, the range of included studies will be expanded to systematic reviews of non-randomised studies (that is, controlled before-after studies, interrupted time-series, small-n studies, observational studies). Such reviews will only be included if the review team and GDG agree that the systematic review of non-randomised studies is of adequate quality, completeness, and applicability to the NHS and to the scope of the guideline.
9.	Context	Care and shared care provided or commissioned by health and social care, in whatever care setting the person resides.
10.	Primary/Critical outcomes	Severity, frequency and duration of the targeted behaviour that challenges. Effects on carer stress and resilience. Quality of life. Fidelity (using validated measures only) Service user and carer satisfaction.
11.	Secondary/Important, but not critical outcomes	Adaptive functioning, including communication skills. Mental and psychological health outcomes (such as mood and anxiety). Adverse effects on other people with a learning disability. Rates of seclusion. Rates of manual restraint. Use of psychoactive medication. Premature death. Rates of placement breakdown. Use of inpatient placements (including out-of-area placements).
12.	Data extraction (selection and coding)	Citations from each search will be downloaded into EndNote and duplicates removed. Records will then be screened against the eligibility criteria of the review. The unfiltered search results will be saved and retained for future potential re-analysis. All primary-level studies included after the first scan of citations will be acquired in full and re-evaluated for eligibility at the time they are being entered into a study database (standardised template created in Microsoft Excel). Eligibility will be confirmed by at least 1 member of the GDG. The GDG are experts in the topic and/or research methodology. Two researchers will extract data into the study database, comparing a sample of each other's work for reliability. Discrepancies or difficulties with coding will be resolved through discussion with members of the GDG.  Data to be extracted:

Item No.	Item	Details
		<p>Study characteristics (study ID, year, intervention/comparison, context or setting, recruitment location , randomised N, diagnosis, target behaviour, IQ cut-off, run in/washout, inclusion/exclusion criteria, group assignment [number of groups, randomisation, N cluster], demographics [age, sex, race, IQ, and so on], funding, publication type, references, risk of bias [sequence generation, allocation concealment, blinding, missing outcome data, selective outcome reporting])</p> <p>Comparisons (N, N post-treatment, N follow-up, intervention, target group, dose type, dose, frequency, duration)</p> <p>Outcomes (outcome type, outcome name, data type, rater, weeks post-randomisation, time point – phase, outcome data [for example, mean, SD, N, events]).</p>
13.	Risk of bias (quality) assessment	The quality of individual studies will be assessed using the appropriate NICE quality assessment checklist. The quality of evidence for each outcome will be assessed using the GRADE approach.
14.	Strategy for data synthesis	<p>Where appropriate, meta-analysis using a random-effects model will be used to combine results from similar studies. Alternatively, a narrative synthesis will be used.</p> <p>If existing reviews are found, the review team with advice from the GDG will assess their quality, completeness, and applicability to the NHS and to the scope of the guideline. If the GDG agree that a systematic review appropriately addresses a review question, we will search for studies conducted or published since the review was conducted, and the GDG will assess if any additional studies could affect the conclusions of the previous review. If new studies could change the conclusions, we will update the review and conduct a new analysis. If new studies could not change the conclusions of an existing review, the GDG will use the existing review to inform their recommendations.</p> <p>Repeated observations on participants: If studies reports results for several periods of follow-up (for example, 4 weeks, 12 weeks and 26 weeks post treatment) the longest follow-up from each study shall be utilised in analyses. If the GDG feel that periods of follow-up are sufficiently distanced by time, we shall consider defining several different outcomes, based on different periods of follow-up, and to perform separate analyses (for example, short-term, medium-term and long-term follow-up).</p> <p>Repeated observations on participants: If studies reports results for several periods of follow-up (for example, 4 weeks, 12 weeks and 26 weeks post treatment) the longest follow-up from each study shall be utilised in analyses. If the GDG feel that periods of follow-up are sufficiently distanced by time, we shall consider defining several different outcomes, based on different periods of follow-up, and to perform separate analyses (for example, short-term, medium-term and long-term follow-up).</p>

Item No.	Item	Details
		<p>Method of dealing with missing data Because imputation of missing data in order to perform a full ITT analysis is controversial, only the results for available participants will be analysed in meta-analysis. However, for dichotomous outcomes a sensitivity analyses will be carried out whereby missing data will be imputed according to worst case scenario. Outcomes from the sensitivity analysis will only be presented if the ITT analysis differs significantly from the available case analysis.</p> <p>GRADE methods While considering all of the below, our decisions will be based a greater amount on those studies that carry the greatest weight within the outcome. If weight is distributed equally, all studies shall be considered equally. Risk of bias: mark down 1 ROB if a single study demonstrates a crucial limitation for 1 criterion or some limitations for multiple, OR if risk of bias across multiple studies is at moderate ROB; mark down 2 if there is a crucial limitation for 1 or more criteria within a study OR if risk of bias across multiple studies is at high ROB. Inconsistency: mark down 1 if <math>I^2 &gt; 40\%</math>; mark down 2 if <math>I^2 &gt; 75\%</math>. We shall also consider the variability in point estimates, overlap of CI and P-value (<math>&lt;0.05</math>) in our decision. Indirectness: review applicability of intervention, population and comparison. Consider down grading if <math>&gt;33\%</math> of population is not relevant, if the intervention is not aimed primarily at reducing the targeted behaviour that challenges, or if the comparison may reduce our confidence in the effect. Imprecision: mark down 1 if optimal information size is not met with multiple studies (Guyatt, 2011); mark down 2 if optimal information size is not met with a single study. Publication bias: Where possible, use funnel plots to determine the presence of publication bias. If this is not possible, and we have a strong suspicion that publication bias is present, mark down a maximum of 1.</p>
15.	Analysis of subgroups or subsets (including sensitivity analyses)	<p>Subgroups include: Population: Health and social care professionals, family carers, paid carers.</p> <p>Sensitivity analyses: Exclude RCT studies with <math>&lt;10</math> participants per arm</p>

### F.3.7 Topic: Organisation and delivery of care

Item No.	Item	Details
1.	Review question(s)	<p>RQ7.1: In people with a learning disability and behaviour that challenges, what are the effective models for transition between services (for example child-adult, adult-older adult, NHS-social care/residential)? To answer this question, consideration should be given to:</p> <p>the structure, design and delivery of care pathways</p> <p>the nature and duration of support provided during transition</p>
2.	Sub-question(s)	RQ#:
3.	Searches	<p>RCT:</p> <p>Major bibliographic databases: CENTRAL (inception to October 2014), CINAHL (inception to October 2014), Embase (inception to October 2014), MEDLINE/PreMEDLINE (inception to October 2014), PsycINFO (inception to October 2014)</p> <p>Topic databases: AEI (inception to October 2014), ASSIA (inception to October 2014), BEI (inception to October 2014), ERIC (inception to October 2014), IBSS (inception to October 2014), SSCI (inception to October 2014), Sociological Abstracts (inception to October 2014), Social Services Abstracts (inception to October 2014)</p> <p>Systematic reviews of RCTs: Major bibliographic databases CDSR (1999 to October 2014), DARE (1999 to October 2014), CINAHL (1999 to October 2014), Embase (1999 to October 2014), MEDLINE/PreMEDLINE (1999 to October 2014), PsycINFO (1999 to October 2014)</p> <p>Topic databases: AEI (1999 to October 2014), ASSIA (1999 to October 2014), BEI (1999 to October 2014), ERIC (1999 to October 2014), IBSS (1999 to October 2014), SSCI (1999 to October 2014), Sociological Abstracts (1999 to October 2014), Social Services Abstracts (1999 to October 2014)</p> <p><i>Note. Conference abstracts will be assessed for eligibility and potentially eligible studies will be checked to determine if they have been published or made available in a full report.</i></p> <p>Other resources of evidence:</p> <ul style="list-style-type: none"> <li>• Reference lists of included studies</li> </ul>

Item No.	Item	Details
		<ul style="list-style-type: none"> <li>• Registered stakeholders</li> <li>• Trial authors and drug companies</li> <li>• Trial registries (<a href="http://www.controlled-trials.com/">http://www.controlled-trials.com/</a>; <a href="https://www.clinicaltrialsregister.eu">https://www.clinicaltrialsregister.eu</a>)</li> <li>• PROSPERO</li> <li>• Non-English-language papers (with English abstracts) will be assessed for eligibility and potentially eligible studies will be checked to determine if they have been published in an English-language journal. Studies that have not been published in an English-language journal will not be included in the review.</li> </ul> <p><i>Note. Unpublished data will only be included where a full trial report is available with sufficient detail to properly assess the risk of bias. Authors of unpublished evidence will be asked for permission to use such data, and will be informed that summary data from the study and the study's characteristics will be published in the full guideline.</i></p>
4.	Condition or domain being studied	<p>Challenging behaviour and learning disabilities.</p> <p>Definitions:</p> <ul style="list-style-type: none"> <li>• Challenging behaviour: <ul style="list-style-type: none"> <li>◦ 'Culturally abnormal behaviour(s) of such an intensity, frequency or duration that the physical safety of the person or others is likely to be placed in serious jeopardy, or behaviour which is likely to seriously limit use of, or result in the person being denied access to, ordinary community facilities'<sup>o</sup>.</li> </ul> </li> <li>• Learning disabilities: <ul style="list-style-type: none"> <li>◦ Heterogeneous conditions, but are defined by 3 core criteria: lower intellectual ability (usually defined as an IQ of less than 70), significant impairment of social or adaptive functioning and onset in childhood. This corresponds to 'mental retardation' as described in the major taxonomies DSM-IV and ICD-10.</li> </ul> </li> </ul>
5.	Participants/population	<p>Children, young people and adults with a mild, moderate, severe or profound learning disability and behaviour that challenges</p> <p>Exclude coexisting conditions (unless these affect interventions, management or support for people with a learning disability and behaviour that challenges).</p>
6.	Intervention(s), exposure(s)	Models for transition between services
7.	Comparator(s)/control	Treatment as usual

<sup>o</sup> Emerson E. Challenging behaviour: analysis and Intervention in people with learning disabilities. 2nd edition. Cambridge: Cambridge University Press; 2001.

Item No.	Item	Details
		No treatment, waitlist control, attention control Any alternative management strategy
8.	Types of study to be included initially	RCTs and systematic reviews of RCTs.  Crossover randomised trials will be included only if data from the first phase is available.  In the first instance, only data from RCTs or systematic reviews of RCTs will be included. If the GDG consider the RCT evidence to be limited in terms of quality, directness or quantity, the range of included studies will be expanded to systematic reviews of non-randomised studies (that is, controlled before-after studies, interrupted time-series, small-n studies, observational studies). Such reviews will only be included if the review team and GDG agree that the systematic review of non-randomised studies is of adequate quality, completeness, and applicability to the NHS and to the scope of the guideline.
9.	Context	Transition between services (for example child-adult, adult-older adult, NHS-social care/residential)
10.	Primary/Critical outcomes	Severity, frequency and duration of the targeted behaviour that challenges. Quality of life. Rates of placement breakdown. Use of inpatient placements (including out-of-area placements). Effects on carer stress and resilience. Service user and carer satisfaction.
11.	Secondary/Important, but not critical outcomes	Adaptive functioning, including communication skills. Mental and psychological health outcomes (such as mood and anxiety). Adverse effects on other people with a learning disability. Rates of seclusion. Rates of manual restraint. Use of psychoactive medication. Premature death.
12.	Data extraction (selection and coding)	Citations from each search will be downloaded into EndNote and duplicates removed. Records will then be screened against the eligibility criteria of the review. The unfiltered search results will be saved and retained for future potential re-

Item No.	Item	Details
		<p>analysis. All primary-level studies included after the first scan of citations will be acquired in full and re-evaluated for eligibility at the time they are being entered into a study database (standardised template created in Microsoft Excel). Eligibility will be confirmed by at least 1 member of the GDG. The GDG are experts in the topic and/or research methodology. Two researchers will extract data into the study database, comparing a sample of each other's work for reliability. Discrepancies or difficulties with coding will be resolved through discussion with members of the GDG.</p> <p>Data to be extracted:</p> <p>Study characteristics (study ID, year, intervention/comparison, context or setting, recruitment location, randomised N, diagnosis, target behaviour, IQ cut-off, run in/washout, inclusion/exclusion criteria, group assignment [number of groups, randomisation, N cluster], demographics [age, sex, race, IQ, and so on], funding, publication type, references, risk of bias [sequence generation, allocation concealment, blinding, missing outcome data, selective outcome reporting])</p> <p>Comparisons (N, N post-treatment, N follow-up, intervention, target group, dose type, dose, frequency, duration)</p> <p>Outcomes (outcome type, outcome name, data type, rater, weeks post-randomisation, time point – phase, outcome data [for example, mean, SD, N, events]).</p>
13.	Risk of bias (quality) assessment	The quality of individual studies will be assessed using the appropriate NICE quality assessment checklist. The quality of evidence for each outcome will be assessed using the GRADE approach.
14.	Strategy for data synthesis	<p>Where appropriate, meta-analysis using a random-effects model will be used to combine results from similar studies. Alternatively, a narrative synthesis will be used.</p> <p>If existing reviews are found, the review team with advice from the GDG will assess their quality, completeness, and applicability to the NHS and to the scope of the guideline. If the GDG agree that a systematic review appropriately addresses a review question, we will search for studies conducted or published since the review was conducted, and the GDG will assess if any additional studies could affect the conclusions of the previous review. If new studies could change the conclusions, we will update the review and conduct a new analysis. If new studies could not change the conclusions of an existing review, the GDG will use the existing review to inform their recommendations.</p>
15.	Analysis of subgroups or subsets (including sensitivity analyses)	<p>Subgroups include:</p> <p>Population: Children and young people; adults</p> <p>Degree of learning disability: mild (an IQ of 50–69), moderate (an IQ of 35–49), severe (an IQ of 20–34) and profound (an IQ of less than 20).</p> <p>Form of challenging behaviour:</p>

Item No.	Item	Details
		<p>Self-injurious behaviour (includes head-banging, scratching, pulling, eye poking, picking, grinding teeth, eating non-foodstuffs, Aggressive behaviour toward others (includes biting and scratching, hitting, pinching, grabbing, hair pulling, throwing objects, verbal abuse, screaming, spitting).</p> <p>Stereotyped behaviour (including repetitive movements, rocking, repetitive speech and repetitive manipulation of objects).</p> <p>Non-person directed behaviour (includes damage to property, hyperactivity, stealing, inappropriate sexualised behaviour, destruction of clothing, incontinence, lack of awareness of danger, withdrawal).</p>

### F.3.8 Topic: Experience of care

Item No.	Item	Details
1.	Review question(s)	<p>RQ8.1: In people with a learning disability and behaviour that challenges, what are their experiences of having a learning disability and behaviour that challenges, of access to services, and of treatment?</p> <p>RQ8.2: For the family carers of people with a learning disability and behaviour that challenges, what are their experiences of caring for people with a learning disability and behaviour that challenges, and what support is available for families, partners and carers?</p>
2.	Sub-question(s)	N/A
3.	Searches	<p>Q8.1, 8.2</p> <p>Major bibliographic databases CINAHL (1999 to October 2014), Embase (1999 to October 2014), MEDLINE/PreMEDLINE (1999 to October 2014), PsycINFO (1999 to October 2014)</p> <p>Topic databases: AEI (1999 to October 2014), ASSIA (1999 to October 2014), BEI (1999 to October 2014), ERIC (1999 to October 2014), IBSS (1999 to October 2014), SSCI (1999 to October 2014), Sociological Abstracts (1999 to October 2014), Social Services Abstracts (1999 to October 2014)</p> <p>Other resources of evidence:</p> <ul style="list-style-type: none"> <li>• Reference lists of included studies</li> </ul>



Item No.	Item	Details
		<ul style="list-style-type: none"> <li>• PROSPERO</li> <li>• Conference abstracts will be assessed for eligibility and potentially eligible studies will be checked to determine if they have been published in full.</li> <li>• Non-English-language papers (with English abstracts) will be assessed for eligibility and potentially eligible studies will be checked to determine if they have been published in an English-language journal. Studies that have not been published in an English-language journal will not be included in the review.</li> </ul> <p>Note. Unpublished data will only be included where a full study report is available with sufficient detail to properly assess the risk of bias. Authors of unpublished evidence will be asked for permission to use such data, and will be informed that <i>summary data from the study and the study's characteristics will be published in the full guideline.</i></p>
4.	Condition or domain being studied	<p>Challenging behaviour and learning disabilities</p> <p>Definitions:</p> <ul style="list-style-type: none"> <li>• Challenging behaviour: <ul style="list-style-type: none"> <li>○ 'Culturally abnormal behaviour(s) of such an intensity, frequency or duration that the physical safety of the person or others is likely to be placed in serious jeopardy, or behaviour which is likely to seriously limit use of, or result in the person being denied access to, ordinary community facilities'<sup>p</sup>.</li> </ul> </li> <li>• Learning disabilities: <ul style="list-style-type: none"> <li>○ Heterogeneous conditions, but are defined by 3 core criteria: lower intellectual ability (usually defined as an IQ of less than 70), significant impairment of social or adaptive functioning and onset in childhood. This corresponds to 'mental retardation' as described in the major taxonomies DSM-IV and ICD-10.</li> </ul> </li> </ul>
5.	Perspective	<p>RQ8.1 People with a learning disability and behaviour that challenges</p> <p>RQ8.2 Family carer of people with a learning disability and behaviour that challenges.</p> <p>Definition of family carer:  Has personal experience of caring for 1 or more persons with CBLD who is a family member;  Has personal contact with a family member who has CBLD, even though that individual may not reside in the family home;  Is not paid to have a personal, continuous relationship with a person with CBLD.</p>

<sup>p</sup> Emerson E. Challenging behaviour: analysis and Intervention in people with learning disabilities. 2nd edition. Cambridge: Cambridge University Press; 2001.

Item No.	Item	Details
		Not all family carers may be related by blood, but choose to support a person with a learning disability in the way described above <sup>9</sup> .
6.	Phenomenon of interest	RQ8.1 The individuals experiences of i) having a learning disability and behaviour that challenges, ii) of access to services, and iii) of treatment.  RQ8.2: The family carers experiences of i) caring for people with a learning disability and behaviour that challenges, ii) the support available.
7.	Comparison	<ul style="list-style-type: none"> <li>• Usual care</li> <li>• No intervention.</li> </ul>
8.	Types of study to be included initially	Systematic reviews and qualitative research.
9.	Setting	Care and shared care provided or commissioned by health and social care, in whatever care setting the person resides.
10.	Primary outcome/Evaluation	<p>RQ8.1</p> <p>Experience of having a learning disability and behaviour that challenges</p> <p>Experience of access to services</p> <p>Experience of treatment</p> <p>RQ8.2</p> <p>Experience of caring for people with a learning disability and behaviour that challenges</p> <p>Experience of the support available</p>
11.	Data extraction (selection and coding)	Citations from each search will be downloaded into EndNote and duplicates removed. Records will then be screened against the eligibility criteria of the review. The unfiltered search results will be saved and retained for future potential re-analysis. All primary-level studies included after the first scan of citations will be acquired in full and re-evaluated for eligibility at the time they are being entered into a study database (standardised template created in Microsoft Excel). Eligibility will be confirmed by at least 1 member of the GDG. The GDG are experts in the topic and/or research methodology. Two researchers will extract data into the study database, comparing a sample of each other's work for reliability. Discrepancies or difficulties with coding will be resolved through discussion with members of the GDG.
12.	Risk of bias (quality) assessment	The quality of individual studies will be assessed using the appropriate NICE quality assessment checklist.
13.	Strategy for data synthesis	Thematic synthesis will be used.

<sup>9</sup> Adapted from: Ward, C. Family Matters: Counting Families In. London: Department of Health; 2001.

Item No.	Item	Details
		If existing reviews are found, the review team with advice from the GDG will assess their quality, completeness, and applicability to the NHS and to the scope of the guideline. If the GDG agree that a systematic review appropriately addresses a review question, we will search for studies conducted or published since the review was conducted, and the GDG will assess if any additional studies could affect the conclusions of the previous review. If new studies could change the conclusions, we will update the review and conduct a new analysis. If new studies could not change the conclusions of an existing review, the GDG will use the existing review to inform their recommendations.
14.	Analysis of subgroups or subsets	N/A

## Appendix G: Research recommendations

The Guideline Development Group has made the following recommendations for research, based on its review of evidence, to improve NICE guidance and patient care in the future.

### G.1 Preventing behaviour that challenges from developing in children aged under 5 years with a learning disability

Can positive behaviour support provided for children aged under 5 years with a learning disability reduce the risk of developing behaviour that challenges?

#### G.1.1 Why this is important

Behaviour that challenges is common in children with a learning disability and can have a considerable impact on them and their family members or carers. It is a common reason for residential placement with associated high costs. Positive behaviour support aims to reduce behaviour that challenges and increase quality of life through teaching new skills and adjusting the environment to promote positive behaviour changes. Early intervention with children at risk of developing behaviour that challenges offers an opportunity to significantly enhance their life and that of their family members or carers.

The question should be addressed by a programme of research that includes:

- developing interventions to prevent behaviour that challenges from developing in children aged under 5 years
- assessing the feasibility of the formal evaluation of the interventions in a randomised controlled trial
- testing the clinical and cost effectiveness of the interventions in a large-scale randomised controlled trial with long-term follow-up
- evaluating the implementation of the interventions in routine care.

### G.2 Interventions to reduce the frequency and extent of moderate to severe behaviour that challenges in community settings

Are interventions based on the science and practice of applied behaviour analysis or antipsychotic medication, or a combination of these, effective in reducing the frequency and severity of behaviour that challenges shown by adults with a learning disability?

#### G.2.1 Why this is important

Behaviour that challenges is common in adults with a learning disability and can have a considerable impact on them and their family members or carers. It is also a common reason for hospital or residential placement. There is limited evidence for the effectiveness of either applied behaviour analysis or antipsychotic medication, or a combination of these in community settings. Little is known about which people respond best to which interventions or about the duration of the interventions. There is considerable evidence of the over use of medication and of limited skills and competence in delivering behavioural interventions.

The question should be addressed by a programme of research evaluating these interventions that includes:

- developing a protocol for assessing moderate to severe behaviour that challenges that:

- characterises the nature and function of the behaviour
- assesses all coexisting problems that may contribute to the behaviour developing or being maintained
- developing protocols for delivering and monitoring the interventions to be tested (including how any currently provided interventions will be stopped)
- assessing the feasibility of the formal evaluation of the interventions in a randomised controlled trial (in particular, recruitment)
- testing the comparative clinical effectiveness (including moderators and mediators) and cost effectiveness of the interventions in a large-scale randomised controlled trial.

### **G.3 Locally accessible care**

Does providing care where people live compared with out-of-area placement lead to improvements in both the clinical and cost effectiveness of care for people with a learning disability and behaviour that challenges?

#### **G.3.1 Why this is important**

Many out-of-area care placements for people with a learning disability and behaviour that challenges are a long way from their home. This can have a considerable impact, limiting a family member or carer's ability to care for the person and leading to poorer outcomes and increased costs. It is widely recognised that locally accessible care settings could be beneficial and could reduce costs but there is no strong empirical evidence to support this. In the absence of such evidence significant numbers of out-of-area placements continue to be made.

The question should be addressed by a programme of research that includes:

- a needs assessment and the care costs of a consecutive cohort of 250 people who have been placed in out-of-area care in a 2-year period
- developing standards for a range of support programmes designed to meet people's needs, which would provide detailed information on:
  - the needs to be met
  - the nature of the care environments
  - the support, including specialist staff, needed
- testing the clinical and cost effectiveness of 'close to home' or home-based care that meet the developed standards (compared with consecutive cohorts in out-of-area placements).

### **G.4 Factors associated with sustained, high-quality residential care**

What factors (including service organisation and management, staff composition, training and supervision, and the content of care and support) are associated with sustained high-quality residential care for people with a learning disability and behaviour that challenges?

#### **G.4.1 Why this is important**

The quality of residential care for people with a learning disability and behaviour that challenges remains an issue of national concern. Reviews (most recently of Winterbourne View Hospital) have identified failings in care. Although recommendations have been made this has not led to a significant and sustained improvement in care. It is important to understand how improvement can be maintained.

The question should be addressed by a programme of research that includes:

- a systematic review of the factors associated with sustained and beneficial change in health and social care organisations
- designing service-level interventions to support the implementation of these standards of care developed from the systematic review
- testing the clinical and cost effectiveness of service-level interventions in residential units through the formal evaluation of a quality improvement programme established to introduce the new standards (the follow-up period should be for a minimum of 3 years after the implementation of the intervention).